

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



27 DEC 2004



(43) International Publication Date  
8 January 2004 (08.01.2004)

PCT

(10) International Publication Number  
WO 2004/003211 A1

(51) International Patent Classification<sup>7</sup>: C12P 12/08, (74) Agents: SOMERVILLE, Deborah, A. et al.; Kenyon & 210/08, A61K 39/395 Kenyon, One Broadway, New York, NY 10004 (US).

(21) International Application Number: PCT/US2002/041372

(22) International Filing Date: 24 December 2002 (24.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: PCT/US02/20332 26 June 2002 (26.06.2002) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
US PCT/US02/20332 (CIP)  
Filed on 26 June 2002 (26.06.2002)

(71) Applicant (for all designated States except US): IM-  
CLONE SYSTEMS INCORPORATED [US/US]; 180  
Varick Street, New York, NY 10014 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): ZHU, Zhenping  
[CN/US]; 9 Boulder Run, Oakland, NJ 07436 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/003211 A1

(54) Title: BISPECIFIC ANTIBODIES THAT BIND TO VEGF RECEPTORS

(57) Abstract: The present invention is directed to production of antigen-binding proteins that bind specifically to an extracellular domains of two different VEGF receptors. The bispecific antigen-binding proteins block activation of the VEGF receptors and are used to reduce or inhibit VEGF-induced cellular functions such as mitogenesis of vascular endothelial cells and migration of leukemia cells. The antigen-binding proteins of the present invention can be monovalent or multivalent, have antigen-binding sites consisting of immunoglobulin heavy chain and light chain variable domains and may further include immunoglobulin constant domains.

## BISPECIFIC ANTIBODIES THAT BIND TO VEGF RECEPTORS

[0001] This application claims the benefit of U.S. Provisional Application Serial No. 60/301,299, filed June 26, 2001 and PCT/US02/20332, filed June 26, 2002.

### FIELD OF THE INVENTION

[0002] The present invention is directed to production of bispecific antigen-binding proteins that bind specifically to the extracellular domains of two different VEGF receptors. The bispecific antigen-binding proteins block activation of the VEGF receptors and are used to reduce or inhibit VEGF-induced cellular functions such as mitogenesis of vascular endothelial cells and migration of leukemia cells. The antigen-binding proteins of the present invention have antigen-binding sites consisting of immunoglobulin heavy chain and light chain variable domains and may be monovalent or bivalent. The antigen-binding proteins can further comprise immunoglobulin constant regions.

### BACKGROUND OF THE INVENTION

[0003] Vascular endothelial growth factors (VEGF), placenta growth factor (PIGF) and their receptors VEGFR-1/Flt-1, VEGFR-2/KDR and VEGFR-3/Flt-4 have important roles in vasculogenesis, angiogenesis and growth of tumor cells.

[0004] Vascular endothelial growth factor (VEGF) is a key regulator of vasculogenesis during embryonic development and angiogenic processes during adult life such as wound healing, diabetic retinopathy, rheumatoid arthritis, psoriasis, inflammatory disorders, tumor growth and metastasis (Ferrara, 1999, Curr. Top. Microbiol. Immunol. 237:1-30; Klagsbrun, M. *et al.*, 1996, Cytokine Rev. 7:259-270; Neufeld, G. *et al.*, 1999, FASEB J. 13:9-22). VEGF is a strong inducer of vascular permeability, stimulator of endothelial cell migration and proliferation, and is an important survival factor for newly formed blood vessels. VEGF binds to and mediates its activity mainly through two tyrosine kinase receptors, VEGF receptor 1 (VEGFR-1), or *fms*-like tyrosine receptor 1 (Flt-1), and VEGF receptor 2 (VEGFR-2), or kinase insert domain-containing receptor (KDR; Flk-1 in mice). Numerous studies have shown that over-expression of VEGF and its receptor play an important role in tumor-associated angiogenesis, and hence in both tumor growth and metastasis (Folkman, J., 1995, Nat. Med. 1:27-31; Zhu, Z. *et al.*, 1999, Invest. New Drugs

17:195-212). This role is further supported by studies demonstrating, for example, inhibition of tumor growth in animal models by antibodies to VEGF (Kim *et al.*, 1993, *Nature* 362:841-844) and its receptors (Zhu, Z. *et al.*, 1998, *Cancer Rex.* 58:3209-3214; Prewett, M. *et al.*, 1999, *Cancer Rex.* 59:5209-5218).

[0005] Flt-1 and KDR have distinct functions in vascular development in embryos. Targeted deletion of genes encoding either receptor in mice is lethal to the embryo, demonstrating the physiological importance of the VEGF pathway in embryonic development. KDR-deficient mice have impaired blood island formation and lack mature endothelial cells, whereas Flt-1 null embryos fail to develop normal vasculature due to defective in the formation of vascular tubes, albeit with abundant endothelial cells. On the other hand, inactivation of Flt-1 signal transduction by truncation of the tyrosine kinase domain did not impair mouse embryonic angiogenesis and embryo development, suggesting that signaling through the Flt-1 receptor is not essential for vasculature development in the embryo. The biological responses of Flt-1 and KDR to VEGF in the adult also appear to be different. It is generally believed that KDR is the main VEGF signal transducer that results in endothelial cell proliferation, migration, differentiation, tube formation, increase of vascular permeability, and maintenance of vascular integrity. Flt-1 possesses a much weaker kinase activity, and is unable to generate a mitogenic response when stimulated by VEGF - although it binds to VEGF with an affinity that is approximately 10-fold higher than KDR. Flt-1, however, has been implicated in VEGF and placenta growth factor (PIGF)-induced migration of monocytes/macrophage and production of tissue factor.

[0006] Apart from VEGF and PIGF, several other growth factors related to VEGF have been identified: VEGF-B, VEGF-C, VEGF-D, and VEGF-E. VEGF-B, like PIGF, binds to Flt-1. VEGF-E is specific for KDR, while VEGF-C and VEGF-D can bind to KDR and another receptor, VEGFR-3 (Flt-4). In addition to their respective specific receptors, these ligands may form heterodimers that bind differentially to various receptor homo- or heterodimers and signal through different pathways.

[0007] Multispecific antibodies have been used in several small-scale clinical trials as cancer imaging and therapy agents, but broad clinical evaluation has been hampered by the lack of efficient production methods. The design of such proteins thus far has been

concerned primarily with providing multispecificity. In few cases has any attention been devoted to providing other useful functions associated with natural antibody molecules.

[0008] In recent years, a variety of chemical and recombinant methods have been developed for the production of bispecific and/or multivalent antibody fragments. For review, see: Holliger, P. and Winter, G., *Curr. Opin. Biotechnol.* 4, 446-449 (1993); Carter, P. *et al.*, *J. Hematotherapy* 4, 463-470 (1995); Plückthun, A. and Pack, P., *Immunotechnology* 3, 83-105 (1997). Bispecificity and/or bivalence has been accomplished by fusing two scFv molecules via flexible linkers, leucine zipper motifs, C<sub>H</sub>C<sub>L</sub>-heterodimerization, and by association of scFv molecules to form bivalent monospecific diabodies and related structures. Multivalency has been achieved by the addition of multimerization sequences at the carboxy or amino terminus of the scFv or Fab fragments, by using for example, p53, streptavidin and helix-turn-helix motifs. For example, by dimerization via the helix-turn-helix motif of an scFv fusion protein of the form (scFv1)-hinge-helix-turn-helix-(scFv2), a tetravalent bispecific miniantibody is produced having two scFv binding sites for each of two target antigens. Improved avidity may also be obtained by providing three functional antigen binding sites. For example, scFv molecules with shortened linkers connecting the V<sub>H</sub> and V<sub>L</sub> domains associate to form a triabody (Kortt *et al.*, 1997, *Protein Eng.* 10:423-433).

[0009] Production of IgG type bispecific antibodies, which resemble IgG antibodies in that they possess a more or less complete IgG constant domain structure, has been achieved by chemical cross-linking of two different IgG molecules or by co-expression of two antibodies from the same cell. One strategy developed to overcome unwanted pairings between two different sets of IgG heavy and light chains co-expressed in transfected cells is modification of the C<sub>H</sub>3 domains of two heavy chains to reduce homodimerization between like antibody heavy chains. Merchant, A. M., *et al.*, (1998) *Nat. Biotechnology* 16, 677-681. In that method, light chain mispairing was eliminated by requiring the use of identical light chains for each binding site of those bispecific antibodies.

[0010] In some cases, it is desirable to maintain functional or structural aspects other than antigen specificity. For example, both complement-mediated cytotoxicity (CMC) and antibody-dependent cell-mediated cytotoxicity (ADCC), which require the presence and function of Fc region heavy chain constant domains, are lost in most bispecific antibodies. Coloma and Morrison created a homogeneous population of bivalent BsAb molecules with an

Fc domain by fusing a scFv to the C-terminus of a complete heavy chain. Co-expression of the fusion with an antibody light chain resulted in the production of a homogeneous population of bivalent, bispecific molecules that bind to one antigen at one end and to a second antigen at the other end (Coloma, M. J. and Morrison, S. L. (1997) *Nat. Biotechnology* 15, 159-163). However, this molecule had a reduced ability to activate complement and was incapable of effecting CMC. Furthermore, the C<sub>H</sub>3 domain bound to high affinity Fc receptor (Fc<sub>γ</sub>R1) with reduced affinity. Zhu *et al.*, PCT/US01/16924, have described the replacement of Ig variable domains with single chain Fvs in order to produce tetrameric Ig-like proteins that (1) are bispecific and bivalent, (2) are substantially homogeneous with no constraints regarding selection of antigen-binding sites, (3) comprise Fc constant domains and retain associated functions, and (4) can be produced in mammalian or other cells without further processing. By a similar method, bispecific monovalent Fab-like proteins can be produced.

#### SUMMARY OF THE INVENTION

[0011] The present invention provides antibodies that have an antigen binding site specific for a first VEGF receptor and an antigen binding site specific for a second VEGF receptor. The antibodies are at least bivalent and may be trivalent, tetravalent or multivalent.

[0012] In a preferred embodiment, the antibody is bispecific, having one antigen binding site specific for a first VEGF receptor and a second antigen binding site specific for a second VEGF receptor. When bound to a VEGF receptor, the antibody effectively blocks interaction between the VEGF receptor and its ligand. Alternatively, or additionally, the antibody is effective to block dimerization of the VEGF receptor proteins. Compared to binding to a single VEGF receptor, dual binding can result in more potent inhibition of VEGF-stimulated cellular functions such as, for example, proliferation of endothelial cells and VEGF- and PIGF-induced migration of human leukemia cells. Antigen-binding proteins are preferably specific for mammalian VEGF receptors or more preferably for human VEGF receptors. VEGF receptors include human KDR, Flt-1 and Flt-4 and their mammalian homologs. In a particularly preferred embodiment, the antibody is specific for KDR and Flt-1.

[0013] In an embodiment of the invention, an antibody can bind specifically to an extracellular domain of a VEGF receptor and neutralizing activation of the VEGF receptor, for example, by block ligand binding or receptor dimerization. In another embodiment of the invention, a bispecific antibody can bind specifically to a VEGF receptor and inhibit angiogenesis. In yet another embodiment of the invention, an antibody can bind specifically to an extracellular domain of a VEGF receptor and reduce tumor growth.

[0014] The invention further contemplates methods of producing bispecific antigen-binding proteins that are specific for two different VEGF receptors. The antigen-binding proteins can be, for example, monovalent or bivalent. In one embodiment, diabodies are produced by coexpression and secretion of two protein chains in bacteria. A first construct encodes the  $V_H$  domain of a first antibody specific for the first VEGF receptor and the  $V_L$  domain of a second antibody specific for the second VEGF receptor. A second construct encodes the  $V_L$  domain of the first antibody and the  $V_H$  domain of the second antibody. The two chains that are expressed associate as a heterodimer with one binding site for each VEGF receptor. In another embodiment, an Ig like antibody is produced wherein a first single chain Fv (scFv) specific for a first VEGF receptor is substituted for each of the  $V_H$  domains and a second scFv specific for a second VEGF receptor is substituted for each of the  $V_L$  domains. The tetrameric antibody formed by association of two heavy and two light chains is bispecific and bivalent, and further comprises immunoglobulin constant regions.

[0015] The invention contemplates methods for neutralizing activation of a first VEGF receptor and a second VEGF receptor which comprise treating cells with a bispecific antibody of the invention. It is further contemplated to use the binding proteins in methods for inhibiting angiogenesis and reducing tumor growth.

#### DESCRIPTION OF THE FIGURES

[0016] Figure 1A is a schematic representation of the DNA constructs used for expression of scFv p1C11, scFv 6.12 and the anti-KDR x anti-Flt-1 bifunctional diabody comprising the p1C11 and Mab 6.12 antigen binding sites in *E. coli*.

[0017] Figure 1B depicts expression and purification of the scFvs and the diabody. The antibodies were expressed in *E. coli*, purified by affinity chromatography, and analyzed

by SDS-PAGE. Lane 1, scFv p1C11; lane 2, scFv 6.12; and lane 3, the bifunctional diabody. Molecular weights of markers are in kDa.

[0018] Figure 2 demonstrates the dual specificity of the anti-KDR x anti-Flt-1 bifunctional diabody. Figure 2A shows simultaneous binding by the diabody to both KDR and Flt-1. Figures 2B and 2C show specific binding of the antibodies to immobilized KDR (B) and Flt-1 (C).

[0019] Figure 3 shows inhibition of binding of KDR and Flt-1 to immobilized VEGF or PIIGF by the anti-KDR x anti-Flt-1 bifunctional diabody. Various concentrations of antibodies were incubated with a fixed concentration of KDR-AP (A) or Flt-1-Fc fusion proteins (B and C) in solution at RT for 1 h, after which the mixtures were transferred to 96-well plates coated with VEGF (A and B) or PIIGF (C).

[0020] Figure 4 shows inhibition of PIIGF and VEGF-induced migration of human leukemia cells by the anti-KDR x anti-Flt-1 bifunctional diabody. Panel A and D: PIIGF (A) and VEGF (D) promote migration of HL60 and HEL cells in a dose-dependent manner. Panels B, C, E and F: Inhibition of PIIGF (B and C), and VEGF (E and F) induced migration of human leukemia cells by the anti-KDR x anti-Flt-1 bifunctional diabody.

[0021] Figure 5 shows inhibition of VEGF-stimulated HUVEC mitogenesis by the anti-KDR x anti-Flt-1 bifunctional diabody.

#### DETAILED DESCRIPTION OF THE INVENTION

[0022] The present invention provides bispecific antibodies that are capable of binding specifically to a first VEGF receptor and to a second VEGF receptor. Of particular interest are antibodies that bind to the extracellular domains of such receptors. An extracellular domain of a VEGF receptor is herein defined includes the ligand-binding domain of the extracellular portion of the receptor, as well as extracellular portions that are involved in dimerization and overlapping epitopes. When bound to the extracellular domain of a VEGF receptor, the antibodies effectively block ligand binding and/or interfere with receptor dimerization. As a result of such binding, the antibodies neutralize activation of the VEGF receptor. Neutralizing a receptor means diminishing and/or inactivating the intrinsic ability of the receptor to transduce a signal. A reliable assay for VEGF receptor neutralization is inhibition of receptor phosphorylation. Methods of determining receptor

phosphorylation are well known in the art and include, for example, measurement of phosphotyrosine with monoclonal antibodies or radioactive labels.

[0023] A natural antibody molecule is composed of two identical heavy chains and two identical light chains. Each light chain is covalently linked to a heavy chain by an interchain disulfide bond. The two heavy chains are further linked to one another by multiple disulfide bonds. Fig. 1 represents the structure of a typical IgG antibody. The individual chains fold into domains having similar sizes (110-125 amino acids) and structures, but different functions. The light chain comprises one variable domain ( $V_L$ ) and one constant domain ( $C_L$ ). The heavy chain comprises one variable domain ( $V_H$ ) and, depending on the class or isotype of antibody, three or four constant domains ( $C_H1$ ,  $C_H2$ ,  $C_H3$  and  $C_H4$ ). In mice and humans, the isotypes are IgA, IgD, IgE, IgG, and IgM, with IgA and IgG further subdivided into subclasses or subtypes. The portion of an antibody consisting of  $V_L$  and  $V_H$  domains is designated "Fv" and constitutes the antigen-binding site. A single chain Fv (scFv) is an engineered protein containing a  $V_L$  domain and a  $V_H$  domain on one polypeptide chain, wherein the N terminus of one domain and the C terminus of the other domain are joined by a flexible linker. "Fab" refers to the portion of the antibody consisting of  $V_L$ ,  $V_H$ ,  $C_L$  and  $C_H1$  domains.

[0024] The variable domains show considerable amino acid sequence variability from one antibody to the next, particularly at the location of the antigen binding site. Three regions, called "hypervariable" or "complementarity-determining regions" (CDR's) are found in each of  $V_L$  and  $V_H$ .

[0025] "Fc" is the designation for the portion of an antibody which comprises paired heavy chain constant domains. In an IgG antibody, for example, the Fc comprises  $C_H2$  and  $C_H3$  domains. The Fc of an IgA or an IgM antibody further comprises a  $C_H4$  domain. The Fc is associated with Fc receptor binding, activation of complement-mediated cytotoxicity and antibody-dependent cellular-cytotoxicity. For natural antibodies such as IgA and IgM, which are complexes of multiple IgG like proteins, complex formation requires Fc constant domains.

[0026] Finally, the "hinge" region separates the Fab and Fc portions of the antibody, providing for mobility of Fabs relative to each other and relative to Fc, as well as including multiple disulfide bonds for covalent linkage of the two heavy chains.

[0027] As used herein, "antibody" refers to a binding protein that comprises antibody  $V_H$  and/or  $V_L$  domains. Antibody specificity refers to selective recognition of the antibody for a particular epitope of an antigen. Natural antibodies, for example, are monospecific. Bispecific antibodies (BsAbs) are antibodies which have two different antigen-binding specificities or sites. Where an antibody has more than one specificity, the recognized epitopes may be associated with a single antigen or with more than one antigen. Antibodies of the present invention are specific for at least a first and a second VEGF receptor, which receptors include, but are not limited to, human KDR, Flt-1, Flt-4 and their non-human homologs.

[0028] Valency refers to the number of binding sites which an antibody has for a particular epitope. For example, a natural IgG antibody is monospecific and bivalent. Where an antibody has specificity for more than one epitope, valency is calculated for each epitope. For example, an antibody which has four binding sites and recognizes a single epitope is tetravalent. An antibody with four binding sites, two binding sites having one specificity and two binding sites having a second specificity, is considered bivalent.

[0029]  $V_L$  and  $V_H$  domains for use in the present invention can be obtained, e.g., from hybridomas or phage display libraries, or from antibodies previously identified as specific for a VEGF receptor. Bispecific antibodies specific for two different receptors are exemplified, although antibodies with more than two binding sites can be engineered that are specific for more than two antigens. In one embodiment, an antibody of the invention binds to KDR and Flt-1. In another embodiment, an antibody of the invention binds to KDR and Flt-4.

[0030] An example of an antibody binding domain that binds to KDR, scFv p1C11 (SEQ ID NOS: 27, 28), was produced from a mouse scFv phage display library. (Zhu *et al.*, 1998). p1C11 blocks VEGF-KDR interaction and inhibits VEGF-stimulated receptor phosphorylation and mitogenesis of human vascular endothelial cells (HUVEC). This scFv binds both soluble KDR and cell surface-expressed KDR on, e.g., HUVEC with high affinity ( $K_d=2.1\text{nM}$ ). Mab 6.12 is an example of an antibody that binds to soluble and cell surface-expressed Flt-1. A hybridoma cell line producing Mab 6.12 has been deposited as ATCC number PTA-3344 under the provisions of the Budapest Treaty on the International

Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and the regulations thereunder (Budapest Treaty).

[0031] In theory, antibodies to an individual growth factor such as VEGF would only neutralize specifically the angiogenic activity of the single ligand. In contrast, antagonistic antibodies to a VEGF receptor will not only block the angiogenic activity of VEGF, but also that of other growth factors exerting their angiogenic effects via the receptor. For example, an anti-KDR antibody will potentially block angiogenic activity of VEGF, VEGF-C, VEGF-D and VEGF-E, whereas an antibody to Flt-1 will inhibit the activity of VEGF, PIGF and VEGF-B. Furthermore, where receptor function involves dimerization, antibodies of the invention are capable of binding to one or both monomers and blocking function. For example, formation of KDR/Flt-1 heterodimers as well as KDR/KDR homodimers can be blocked by antibodies that are specific for KDR. Antibodies specific for Flt-1 can block formation of KDR/Flt-1 heterodimers and Flt-1/Flt-1 homodimers.

[0032] Antibodies of the present invention have two or more binding sites and are at least bispecific. That is, the antibodies may be bispecific even in cases where there are more than two binding sites. Antibodies of the invention include, for example, multivalent single chain antibodies, diabodies and triabodies, as well as antibodies having the constant domain structure of naturally-occurring antibodies. The antibodies can be wholly from a single species, or be chimerized or humanized. For an antibody with more than two antigen binding sites, some binding sites may be identical, so long as the protein has binding sites for two or more different antigens. That is, whereas a first binding site is specific for a first VEGF receptor, a second binding site is specific for a second, different VEGF receptor. In a preferred embodiment, the antibodies are bispecific. In a more preferred embodiment, the antibodies are designed such that a population of the antibodies is homogeneous (*i.e.*, each and every antibody in the population has a first binding site specific for a first VEGF receptor and a second binding site specific for a second VEGF receptor).

[0033] Like natural antibodies, an antigen binding site of an antibody of the invention typically contains six complementarity determining regions (CDRs) which contribute in varying degrees to the affinity of the binding site for antigen. There are three heavy chain variable domain CDRs (CDRH1, CDRH2 and CDRH3) and three light chain variable domain CDRs (CDRL1, CDRL2 and CDRL3). The extent of CDR and framework

regions (FRs) is determined by comparison to a compiled database of amino acid sequences in which those regions have been defined according to variability among the sequences.

[0034] Also included within the scope of the invention are functional antigen binding sites comprised of fewer CDRs (*i.e.*, where binding specificity is determined by three, four or five CDRs). For example, less than a complete set of 6 CDRs may be sufficient for binding. In an embodiment of the invention, a binding protein specific for a VEGF receptor can consist of a single domain, *i.e.*, a  $V_H$  or a  $V_L$  domain will bind specifically with high affinity.

[0035] Example of antibodies wherein binding affinity and specificity are contributed primarily by one or the other variable domain are known in the art. See, e.g., Jeffrey, P.D. et al., 1993, Proc. Natl. Acad. Sci. U S A 90:10310-10314, which discloses an anti-digoxin antibody which binds to digoxin primarily by the antibody heavy chain. Accordingly, single antibody domains can be identified that bind to VEGF receptors. Such single domain antibodies can be obtained, for example, from naturally occurring antibodies, or Fab or scFv phage display libraries. It is understood that, to make a single domain antibody from an antibody comprising a  $V_H$  and a  $V_L$  domain, certain amino acid substitutions outside the CDR regions may be desired to enhance expression or solubility. For example, it may be necessary to modify amino acid residues that would otherwise be buried in the  $V_H$ - $V_L$  interface.

[0036] More recently, antibodies that are homodimers of heavy chains have been discovered in camelids (camels, dromedaries and llamas). These heavy chain antibodies are devoid of light chains and the first constant domain. (See, e.g., Muyldermans, S., 2001, J. Biotechnol. 74:277-302) The reduced-size antigen binding fragments are well expressed in bacteria, bind to antigen with high affinity, and are very stable. Phage display libraries of single domain antibodies (*i.e.*, having a single variable domain that can be a light chain or a heavy chain variable domain) can be produced and screened in the same manner as scFv and Fab libraries. Scaffolds for such single domain antibodies can be modified mouse or human variable domains. It is noted that single antibody domains can bind antigen in a variety of antigen binding modes. That is, the primary antibody-antigen interactions are not limited to amino acid residues corresponding to CDRs of  $V_H$ - $V_L$  containing antibodies, and

consideration can be given to binding interactions outside of CDR residues when optimizing the binding characteristics of such antibodies.

[0037] The antibodies of the present invention bind to VEGF receptors preferably with an affinity comparable to or greater than that of the natural ligand. Affinity, represented by the equilibrium constant for the association of an antigen with an immunoglobulin molecule ( $K$ ), measures the binding strength between an antigenic determinant and an antigen binding site, irrespective of the number of binding sites.  $K_d$ , the dissociation constant, is the reciprocal of  $K$ . An antigenic determinant, also known as an epitope, is the site on an antigen at which a given antibody binds. Typical values of  $K_d$  are  $10^{-5}$  M to  $10^{-11}$  M. Any  $K_d$  greater than  $10^{-4}$  M is considered to be non-specific binding.

[0038] Avidity is a measure of the strength of binding between an immunoglobulin and its antigen. Unlike affinity, which measures the strength of binding at each binding site, avidity is determined by both the affinity and the number of antigen specific binding sites (valency) of an immunoglobulin molecule.

[0039] The antibodies of the invention may comprise only immunoglobulin variable domains, optionally linked by amino acid sequences of synthetic origin. For example, a typical diabody has two Fv domains and comprises two chains - the first chain incorporating the heavy chain variable domain of a first antibody linked to the light chain variable domain of a second antibody, and the second chain comprising the light chain variable domain of the first antibody linked to the heavy chain variable domain of the second antibody. The domains are typically connected by a flexible polypeptide linker of about 5 to 10 amino acid residues, such as, for example, the 5 amino acid sequence Gly-Gly-Gly-Gly-Ser or the 10 amino acid sequence (Gly-Gly-Gly-Gly-Ser)<sub>2</sub>. Pairing of first and second chains is favored over pairing of like chains, and a substantially homogeneous population of diabodies is achieved.

[0040] In certain embodiments, antibodies of the invention further comprise immunoglobulin constant regions of one or more immunoglobulin classes. Immunoglobulin classes include IgG, IgM, IgA, IgD, and IgE isotypes and, in the case of IgG and IgA, their subtypes. In a preferred embodiment, an antibody of the invention has a constant domain structure of an IgG type antibody, but has four antigen binding sites. This is accomplished by substituting a complete antigen binding sites (e.g., a single chain Fv) for each of the

immunoglobulin variable domains. The four antigen-binding sites preferably comprise two binding sites for each of two different binding specificities.

[0041] An antigen binding site for inclusion in an antibody having desired binding characteristics is obtained by a variety of methods. The amino acid sequences of the  $V_L$  and/or  $V_H$  portions of a selected binding domain correspond to a naturally-occurring antibody or are chosen or modified to obtain desired immunogenic or binding characteristics. For example,  $V_L$  and  $V_H$  domains can be obtained directly from a monoclonal antibody which has the desired binding characteristics. Anti-VEGFR-2 monoclonal antibodies include DC101 (rat anti-mouse VEGFR-2; deposited as ATCC HB 11534), M25.18A1 (mouse anti-mouse VEGFR-2; deposited as ATCC HB 12152), and M73.24 (mouse anti-mouse VEGFR-2; deposited as ATCC HB 12153). Anti-VEGFR-1 monoclonal antibodies include KM1730 (deposited as FERM BP-5697), KM1731 (deposited as FERM BP-5718), KM1732 (deposited as FERM BP-5698), KM1748 (deposited as FERM BP-5699), and KM1750 (deposited as FERM BP-5700), disclosed in WO 98/22616, WO 99/59636, Australian accepted application no. AU 1998 50666 B2, and Canadian application no. CA 2328893.

[0042] Alternatively,  $V_L$  and  $V_H$  domains can be from libraries of V gene sequences from a mammal of choice. Elements of such libraries express random combinations of  $V_L$  and/or  $V_H$  domains and are screened with any desired antigen to identify those elements which have desired binding characteristics. Particularly preferred is a human V gene library. Methods for such screening are known in the art.  $V_L$  and  $V_H$  domains from a selected non-human source may be incorporated into chimeric antibodies. For example, for administration to a human, it may be desired to use a bispecific antibody with functional constant domains wherein the  $V_L$  and  $V_H$  domains have been selected from a non-human source. To maximize constant domain associated function or to reduce immunogenicity of the antibody, human constant regions are preferred.

[0043] Alternatively, a bispecific antibody can be made that is "humanized." Humanized variable domains are constructed in which amino acid sequences which comprise one or more complementarity determining regions (CDRs) of non-human origin are grafted to human framework regions (FRs). For examples, see: Jones, P. T. *et al.*, (1996) *Nature* 321, 522-525; Riechman, L. *et al.*, (1988) *Nature* 332, 323-327; U.S. Patent No. 5,530,101 to Queen *et al.* A humanized construct is particularly valuable for elimination of adverse

immunogenic characteristics, for example, where an antigen binding domain from a non-human source is desired to be used for treatment in a human. Variable domains have a high degree of structural homology, allowing easy identification of amino acid residues within variable domains which correspond to CDRs and FRs. See, e.g., Kabat, E.A., *et al.* (1991) *Sequences of Proteins of Immunological Interest*. 5th ed. National Center for Biotechnology Information, National Institutes of Health, Bethesda, MD. Thus, amino acids which participate in antigen binding are easily identified. In addition, methods have been developed to preserve or to enhance affinity for antigen of humanized binding domains comprising grafted CDRs. One way is to include in the recipient variable domain the foreign framework residues which influence the conformation of the CDR regions. A second way is to graft the foreign CDRs onto human variable domains with the closest homology to the foreign variable region. Queen, C. *et al.*, (1989) *Proc. Natl. Acad. Sci. USA* 86, 10029-10033. CDRs are most easily grafted onto different FRs by first amplifying individual FR sequences using overlapping primers which include desired CDR sequences, and joining the resulting gene segments in subsequent amplification reactions. Grafting of a CDR onto a different variable domain can further involve the substitution of amino acid residues which are adjacent to the CDR in the amino acid sequence or packed against the CDR in the folded variable domain structure which affect the conformation of the CDR. Humanized domains of the invention therefore include human antibodies which comprise one or more non-human CDRs as well as such domains in which additional substitutions or replacements have been made to preserve or enhance binding characteristics.

[0044] Antibodies of the invention also include antibodies which have been made less immunogenic by replacing surface-exposed residues to make the antibody appear as self to the immune system (Padlan, E.A. (1991) *Mol. Immunol.* 28, 489-498). Antibodies have been modified by this process with no loss of affinity (Roguska *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91, 969-973). Because the internal packing of amino acid residues in the vicinity of the antigen binding site remains unchanged, affinity is preserved. Substitution of surface-exposed residues according to the invention for the purpose of reduced immunogenicity does not mean substitution of CDR residues or adjacent residues which influence binding characteristics.

[0045] The invention contemplates binding domains which are essentially human.

Human binding domains can be obtained from phage display libraries wherein human heavy or light chain variable domains or combinations thereof are displayed on the surface of filamentous phage (See, e.g., McCafferty *et al.* (1990) *Nature* 348, 552-554; Aujame *et al.* (1997) *Human Antibodies* 8, 155-168). Combinations of variable domains are typically displayed on filamentous phage in the form of Fabs or scFvs. The library is screened for phage bearing combinations of variable domains having desired antigen binding characteristics. Preferred variable domains and variable domain combinations display high affinity for a selected antigen and little cross-reactivity to other related antigens. By screening very large repertoires of antibody fragments, (see e.g., Griffiths *et al.* (1994) *EMBO J.* 13, 3245-3260) a good diversity of high affinity Mabs are isolated, with many expected to have sub-nanomolar affinities for the desired antigen.

[0046] Alternatively, human binding domains can be obtained from transgenic animals into which unarranged human Ig gene segments have been introduced and in which the endogenous mouse Ig genes have been inactivated (reviewed in Brüggemann and Taussig (1997) *Curr. Opin. Biotechnol.* 8, 455-458). Preferred transgenic animals contain very large contiguous Ig gene fragments that are over 1 Mb in size (Mendez *et al.* (1997) *Nature Genet.* 15, 146-156) but human Mabs of moderate affinity can be raised from transgenic animals containing smaller gene loci (See, e.g., Wagner *et al.* (1994) *Eur. J. Immunol.* 42, 2672-2681; Green *et al.* (1994) *Nature Genet.* 7, 13-21).

[0047] In a physiological immune response, mutation and selection of expressed antibody genes leads to the production of antibodies having high affinity for their target antigen. The  $V_L$  and  $V_H$  domains incorporated into antibodies of the invention can similarly be subject to *in vitro* mutation and screening procedures to obtain high affinity variants.

[0048] Binding domains of the invention include those for which binding characteristics have been improved by direct mutation or by methods of affinity maturation. Affinity and specificity may be modified or improved by mutating CDRs and screening for antigen binding sites having the desired characteristics (See, e.g., Yang *et al.* (1995) *J. Mol. Bio.* 254, 392-403). CDRs are mutated in a variety of ways. One way is to randomize individual residues or combinations of residues so that in a population of otherwise identical antigen binding sites, all twenty amino acids, or a subset thereof, are found at particular

positions. Alternatively, mutations are induced over a range of CDR residues by error prone PCR methods (See, e.g., Hawkins *et al.* (1992) *J. Mol. Bio.* 226, 889-896). Phage display vectors containing heavy and light chain variable region genes are propagated in mutator strains of *E. coli* (See, e.g., Low *et al.* (1996) *J. Mol. Bio.* 250, 359-368). These methods of mutagenesis are illustrative of the many methods known to one of skill in the art.

[0049] Each variable domain of the antibodies of the present invention may be a complete immunoglobulin heavy or light chain variable domain, or it may be a functional equivalent or a mutant or derivative of a naturally occurring domain, or a synthetic domain constructed, for example, *in vitro* using a technique such as one described in WO 93/11236 (Medical Research Council *et al.*/Griffiths *et al.*). For instance, it is possible to join together domains corresponding to portions of antibody variable domains (*i.e.*, variable domains which are missing at least one amino acid). The important characterizing feature is the ability of each variable domain to associate with a complementary variable domain to form an antigen binding site.

[0050] In another aspect of the invention, the antibodies can be chemically or biosynthetically linked to anti-tumor agents or detectable signal-producing agents. Anti-tumor agents linked to an antibody include any agents which destroy or damage a tumor to which the antibody has bound or in the environment of the cell to which the antibody has bound. For example, an anti-tumor agent is a toxic agent such as a chemotherapeutic agent or a radioisotope. Suitable chemotherapeutic agents are known to those skilled in the art and include anthracyclines (e.g. daunomycin and doxorubicin), methotrexate, vindesine, neocarzinostatin, cis-platinum, chlorambucil, cytosine arabinoside, 5-fluorouridine, melphalan, ricin and calicheamicin. The chemotherapeutic agents are conjugated to the antibody using conventional methods (See, e.g., Hermentin and Seiler (1988) *Behring Inst. Mitt.* 82, 197-215).

[0051] Detectable signal-producing agents are useful *in vivo* and *in vitro* for diagnostic purposes. The signal producing agent produces a measurable signal which is detectable by external means, usually the measurement of electromagnetic radiation. For the most part, the signal producing agent is an enzyme or chromophore, or emits light by fluorescence, phosphorescence or chemiluminescence. Chromophores include dyes which

absorb light in the ultraviolet or visible region, and can be substrates or degradation products of enzyme catalyzed reactions.

[0052] The invention further contemplates antibodies to which target or reporter moieties are linked. Target moieties are first members of binding pairs. Anti-tumor agents, for example, are conjugated to second members of such pairs and are thereby directed to the site where the antibody is bound. A common example of such a binding pair is avidin and biotin. In a preferred embodiment, biotin is conjugated to an antibody of the invention, and thereby provides a target for an anti-tumor agent or other moiety which is conjugated to avidin or streptavidin. Alternatively, biotin or another such moiety is linked to an antibody of the invention and used as a reporter, for example in a diagnostic system where a detectable signal-producing agent is conjugated to avidin or streptavidin.

[0053] Suitable radioisotopes for use as anti-tumor agents are also known to those skilled in the art. For example,  $^{131}\text{I}$  or  $^{211}\text{At}$  is used. These isotopes are attached to the antibody using conventional techniques (See, e.g., Pedley *et al.* (1993) *Br. J. Cancer* 68, 69-73). Alternatively, the anti-tumor agent which is attached to the antibody is an enzyme which activates a prodrug. In this way, a prodrug is administered which remains in its inactive form until it reaches the tumor site where it is converted to its cytotoxin form once the antibody complex is administered. In practice, the antibody-enzyme conjugate is administered to the patient and allowed to localize in the region of the tissue to be treated. The prodrug is then administered to the patient so that conversion to the cytotoxic drug occurs in the region of the tissue to be treated. Alternatively, the anti-tumor agent conjugated to the antibody is a cytokine such as interleukin-2 (IL-2), interleukin-4 (IL-4) or tumor necrosis factor alpha (TNF- $\alpha$ ). The antibody targets the cytokine to the tumor so that the cytokine mediates damage to or destruction of the tumor without affecting other tissues. The cytokine is fused to the antibody at the DNA level using conventional recombinant DNA techniques.

[0054] The proteins of the invention can be fused to additional amino acid residues such as a peptide tag to facilitate isolation or purification, or a signal sequence to promote secretion or membrane transport in any particular host in which the protein is expressed.

[0055] Vectors for construction and expression of antibodies of the invention in bacteria are available which contain secretion signal sequences and convenient restriction

cloning sites.  $V_L$  and  $V_H$  gene combinations encoding binding sites specific for a particular antigen are isolated from cDNA of B cell hybridomas. Alternatively, random combinations of  $V_L$  and  $V_H$  genes are obtained from genomic DNA and the products then screened for binding to an antigen of interest. Typically, the polymerase chain reaction (PCR) is employed for cloning, using primers which are compatible with restriction sites in the cloning vector. See, e.g., Dreher, M.L. et al. (1991) *J. Immunol. Methods* 139:197-205; Ward, E.S. (1993) *Adv. Pharmacol.* 24:1-20; Chowdhury, P.S. and Pastan, I. (1999) *Nat. Biotechnol.* 17:568-572.

[0056] To express antibodies with selected or random combinations of  $V_L$  and  $V_H$  domains, V genes encoding those domains are assembled into a bacterial expression vector. For example, a vector can be used which has sequences encoding a bacterial secretion signal sequence and a peptide linker and which has convenient restriction sites for insertion of  $V_L$  and  $V_H$  genes. Alternatively, it might be desired to first assemble all necessary coding sequences (e.g., secretion signal,  $V_L$ ,  $V_H$  and linker peptide) into a single sequence, for example by PCR amplification using overlapping primers, followed by ligation into a plasmid or other vector. Where it is desired to provide a specific combination of  $V_L$  and  $V_H$  domains, PCR primers specific to the sequences encoding those domains are used. Where it is desired to create a diverse combinations of a large number of  $V_L$  and  $V_H$  domain, mixtures of primers are used which amplify multiple sequences.

[0057] Preferred diabodies of the invention are made by expressing 1) a first polypeptide comprising a heavy chain variable domain corresponding to a first specificity connected to a light chain variable domain of a second specificity; and 2) a second polypeptide comprising a light chain variable domain corresponding to the first specificity connected to the heavy chain variable domain of the second specificity. Diabodies are commonly produced in *E. coli* using DNA constructs which comprise bacterial secretion signal sequences at the start of each polypeptide chain.

[0058] For certain binding proteins of the invention, expression in other host cells may be desired. For example, binding proteins comprising constant domains are often more efficiently expressed in eukaryotic cells, including yeast, insect, vertebrate and mammalian cells. It will be necessary to use such cells where it is desired that the expressed product be glycosylated. The DNA fragments coding for the first and second polypeptides can be

cloned, e.g., into HCMV vectors designed to express human light chains of human heavy chains in mammalian cells. (See, e.g., Bendig, *et al.*, U.S. Patent 5,840,299; Maeda, *et al.* (1991) *Hum. Antibod. Hybridomas* 2, 124-134). Such vectors contain the human cytomegalovirus (HCMV) promoter and enhancer for high level transcription of the light chain and heavy chain constructs. In a preferred embodiment, the light chain expression vector is pKN100 (gift of Dr. S. Tarzan Jones, MRC Collaborative Center, London, England), which encodes a human kappa light chain, and the heavy chain expression vector is pG1D105 (gift of Dr. S. Tarzan Jones), which encodes a human gamma-1 heavy chain. Both vectors contain HCMV promoters and enhancers, replication origins and selectable markers functional in mammalian cells and *E. coli*.

[0059] A selectable marker is a gene which encodes a protein necessary for the survival or growth of transformed host cells grown in a selective culture medium. Typical selectable markers encode proteins that (a) confer resistance to antibiotics or other toxins, e.g. ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g. the gene encoding D-alanine racemase for *Bacilli*. A particularly useful selectable marker confers resistance to methotrexate. For example, cells transformed with the DHFR selection gene are first identified by culturing all of the transformants in a culture medium that contains methotrexate (Mtx), a competitive antagonist of DHFR. An appropriate host cell when wild-type DHFR is employed is the Chinese hamster ovary (CHO) cell line deficient in DHFR activity, prepared and propagated as described by Urlaub and Chasin (1980) *Proc. Natl. Acad. Sci. USA* 77, 4216. The transformed cells are then exposed to increased levels of methotrexate. This leads to the synthesis of multiple copies of the DHFR gene, and, concomitantly, multiple copies of other DNA comprising the expression vectors, such as the DNA encoding the antibody or antibody fragment. In another example, mutant myeloma cells that are deficient for thymidine kinase (TK) are unable to use exogenously supplied thymidine when aminopterin is used to block DNA synthesis. Useful vectors for transfection carry an intact TK gene which allows growth in media supplemented with thymidine.

[0060] Where it is desired to express a gene construct in yeast, a suitable selection gene for use in yeast is the trp1 gene present in the yeast plasmid YRp7. Stinchcomb *et al.*, 1979 *Nature*, 282, 39; Kingsman *et al.*, 1979, *Gene* 7, 141. The trp1 gene provides a

selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1. Jones (1977) *Genetics* 85, 12. The presence of the *trp1* lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan. Similarly, Leu2-deficient yeast strains (ATCC 20,622 or 38,626) are complemented by known plasmids bearing the Leu2 gene.

[0061] Preferred host cells for transformation of vectors and expression of antibodies of the present invention are bacterial cells, yeast cells and mammalian cells, e.g., COS-7 cells, chinese hamster ovary (CHO) cells, and cell lines of lymphoid origin such as lymphoma, myeloma, or hybridoma cells. The transformed host cells are cultured by methods known in the art in a liquid medium containing assimilable sources of carbon, e.g. carbohydrates such as glucose or lactose, nitrogen, e.g. amino acids, peptides, proteins or their degradation products such as peptones, ammonium salts or the like, and inorganic salts, e.g. sulfates, phosphates and/or carbonates of sodium, potassium, magnesium and calcium. The medium furthermore contains, for example, growth-promoting substances, such as trace elements, for example iron, zinc, manganese and the like.

[0062] Antibodies of the instant invention have dual specificity and capable of binding to two different antigens simultaneously. The different antigens can be located on different cells or on the same cell. Cross linking of antigen can be shown *in vitro*, for example by providing a solid surface to which a first antigen has been bound, adding a bispecific antibodies specific for the first antigen and a second antigen for which the binding protein is also specific and detecting the presence of bound second antigen.

[0063] Antibodies of the invention can of block the interaction between two receptors and their respective ligands. For example, a diabody specific for KDR and Flt-1 inhibits VEGF induced cell migration as well as PIGF induced cell migration. In this case, combination of two receptor binding specificities, either as a mixture of single chains antibodies (scFvs) or in a bispecific diabody, is more efficacious in inhibiting cell migration than the individual parent antibodies.

[0064] Compared to antibodies that are monospecific, bispecific antibodies can be more potent inhibitors of cellular function. For example, VEGF-stimulated cellular functions such as, for example, proliferation of endothelial cells and VEGF- and PI GF-induced

migration of human leukemia cells can be more efficiently inhibited by bispecific antibodies, even where affinity for one or both of the two target antigens is reduced. In one embodiment of the invention, a diabody was made that was specific for KDR and Flt-1. scFv corresponding to either of the target antigens was unable to completely inhibit VEGF- or PIGF-induced cell migration, even at the highest scFv concentrations tested. In contrast, a diabody specific for both of the target antigens completely abolished cell migration, even though the affinity of the diabody for Flt-1 was reduced compared to the corresponding scFv.

[0065] The antibodies of the present invention are useful for treating diseases in humans and other mammals. The antibodies are used for the same purposes and in the same manner as heretofore known for natural and engineered antibodies. The present antibodies thus can be used *in vivo* and *in vitro* for investigative, diagnostic or treatment methods which are well known in the art.

[0066] The present antibodies can be administered for therapeutic treatments to a patient suffering from a tumor in an amount sufficient to prevent or reduce the progression of the tumor, e.g., the growth, invasiveness, metastases and/or recurrence of the tumor. An amount adequate to accomplish this is defined as a therapeutically effective dose. Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's own immune system. Dosing schedules will also vary with the disease state and status of the patient, and will typically range from a single bolus dosage or continuous infusion to multiple administrations per day (e.g., every 4-6 hours), or as indicated by the treating physician and the patient's condition. Antibodies of the invention can be administered in a single dosages as high as 40 mg/kg body-weight or higher. More preferably, the antibodies are administered in dosages that range from 0.2 mg/kg to 20 mg/kg body-weight. It should be noted, however, that the present invention is not limited to any particular dose.

[0067] The present invention can be used to treat any suitable tumor, including, for example, tumors of the breast, heart, lung, small intestine, colon, spleen, kidney, bladder, head and neck, ovary, prostate, brain, pancreas, skin, bone, bone marrow, blood, thymus, uterus, testicles, cervix or liver. Tumors of the present invention preferably have aberrant expression or signaling of VEGFR. Enhanced signaling by VEGFR has been observed in many different human cancers. High levels of VEGFR-2 are expressed by endothelial cells

that infiltrate gliomas (Plate, K. et al., (1992) *Nature* 359:845-848). VEGFR-2 levels are specifically upregulated by VEGF produced by human glioblastomas (Plate, K. et al. (1993) *Cancer Res.* 53:5822-5827). The finding of high levels of VEGFR-2 expression in glioblastoma associated endothelial cells (GAEC) indicates that receptor activity is probably induced during tumor formation since VEGFR-2 transcripts are barely detectable in normal brain endothelial cells. This upregulation is confined to the vascular endothelial cells in close proximity to the tumor.

[0068] The antibodies of the invention are also to be used in combined treatment methods. The bispecific antibodies can be administered with an anti-neoplastic agent such as a chemotherapeutic agent or a radioisotope. Suitable chemotherapeutic agents are known to those skilled in the art and include anthracyclines (e.g. daunomycin and doxorubicin), paclitaxel, irinotecan (CPT-11), topotecan, methotrexate, vindesine, neocarzinostatin, cisplatin, chlorambucil, cytosine arabinoside, 5-fluorouridine, melphalan, ricin, calicheamicin, and combinations thereof. A bispecific antibody and an anti-neoplastic agent are administered to a patient in amounts effective to inhibit angiogenesis and reduce tumor growth. The antibodies are also to be administered in combination with other treatment regimes. For example, bispecific antigen binding proteins of the invention can be administered with radiation, either external (external beam radiation therapy) or internal (brachytherapy).

[0069] It is understood that antibodies of the invention, where used in the human body for the purpose of diagnosis or treatment, will be administered in the form of a composition additionally comprising a pharmaceutically-acceptable carrier. Suitable pharmaceutically acceptable carriers include, for example, one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. Pharmaceutically acceptable carriers may further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the binding proteins. The compositions of this invention may be in a variety of forms. These include, for example, solid, semi-solid and liquid dosage forms, such as tablets, pills, powders, liquid solutions, dispersions or suspensions, liposomes, suppositories, injectable and infusible solutions. The preferred form

depends on the intended mode of administration and therapeutic application. The preferred compositions are in the form of injectable or infusible solutions.

[0070] Therapeutic compositions of this invention are similar to those generally used for passive immunization of humans with antibodies as are known to those of skill in the art, and include but are not limited to intraveneous, intraperitoneal, subcutaneous, and intramuscular administration. Further, it is understood that combination treatments may involve administration of antibodies and, e.g., chemotherapeutic agents, by different methods.

[0071] It is to be understood and expected that variations in the principles of invention herein disclosed may be made by one skilled in the art and it is intended that such modifications are to be included within the scope of the present invention.

[0072] The examples which follow further illustrate the invention, but should not be construed to limit the scope of the invention in any way. Detailed descriptions of conventional methods, such as those employed in the construction of vectors and plasmids, the insertion of genes encoding polypeptides into such vectors and plasmids, the introduction of plasmids into host cells, and the expression and determination thereof of genes and gene products can be obtained from numerous publications, including Sambrook, J. *et al.*, (1989) Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., Cold Spring Harbor Laboratory Press. All references mentioned herein are incorporated in their entirety.

EXAMPLE 1: Materials and Methods***Cell lines.***

[0073] A hybridoma cell line (ATC No. PTA-334) producing the anti-Flt-1 antibody, Mab6.12 (IgG1, κ), was established at ImClone Systems Incorporated (New York, NY) from a mouse immunized with a recombinant form of the receptor. Primary-cultured human umbilical vein endothelial cells (HUVEC) were obtained from Dr. S. Rafi at Cornell Medical Center, New York, and maintained in EBM-2 medium (Clonetics, Walkersville, MD) at 37°C, 5% CO<sub>2</sub>. The leukemia cell lines, HL60 and HEL, were maintained in RPMI containing 10% of fetal calf serum and grown at 37°C with 5% CO<sub>2</sub>.

***Proteins and antibodies.***

[0074] The soluble fusion protein KDR-alkaline phosphatase (AP) was expressed in stably transfected NIH 3T3 and purified from cell culture supernatant by affinity chromatography using immobilized monoclonal antibody to AP as described by Lu, D., *et al.*, 2000, *J. Biol. Chem.*, 275:14321-14330. VEGF165 protein was expressed in baculovirus and purified following the procedures described. *Id.* PIGF and Flt-1-Fc fusion proteins were purchased from R&D Systems (Minneapolis, MN).

***Preparation of scFv specific for Flt-1.***

[0075] The V<sub>H</sub> and V<sub>L</sub> genes of Mab 6.12 were cloned by RT-PCR from mRNA isolated from the hybridoma cells, following the procedures of Bendig *et al.* (1996) In: *Antibody Engineering: A Practical Approach*, McCafferty, J., Hoogenboom, H.R., Chiswell, D.J., eds., Oxford University Press, Incorporated; p147-168. Eleven 5' primers, specifically designed to hybridize to the 5' ends of mouse antibody light chain leader sequences, and one 3' primer that hybridizes to the 5' end of mouse κ light chain constant region, were used to clone the V<sub>L</sub> gene. Twelve 5' primers, specifically designed to hybridize to the 5' ends of mouse antibody heavy chain leader sequences, and one 3' primer that hybridizes to the 5' end of mouse IgG1 heavy chain constant region were used to clone the V<sub>H</sub> gene. In total, twenty-three PCR reactions, eleven for the V<sub>L</sub> gene and twelve for the V<sub>H</sub> gene, were carried out. All PCR-generated fragments with sizes between 400 to 500 base pairs were cloned into the pCR® 2.1 vector as described in the manufacturer's instruction (TA Cloning® Kit, Invitrogen, Carlsbad, CA), followed by transformation of *E. coli* strain, XL-1.

[0076] PCR fragments encoding the V<sub>L</sub> and the V<sub>H</sub> genes of MAB 6.12 were used to assemble scFv 6.12, using overlapping PCR. In this scFv, the C-terminal of Mab 6.12 V<sub>H</sub> is

linked to the N-terminal of Mab 6.12 V<sub>L</sub> via a 15 amino acid linker, (Glycine-Glycine-Glycine-Serine)<sub>3</sub>, or (GGGGS)<sub>3</sub> (Fig. 1A). The scFv 6.12-encoding gene was then cloned into vector pCANTAB 5E (Amersham Pharmacia Biotech, Piscataway, NJ) for the expression of the soluble scFv protein. The amino acid and nucleotide sequences for the Mab 6.12 V<sub>H</sub> domain are given by SEQ ID NOS:41 and 49, respectively. Similarly, the amino acid and nucleotide sequences for the Mab 6.12 V<sub>L</sub> domain are presented by SEQ ID NOS:42 and 50. Amino acid sequences for CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 are presented by SEQ ID NOS:35, 36, 37, 38, 39, and 40, respectively. The corresponding nucleotide sequences are presented by SEQ ID NOS:43 to 48.

***Preparation and biopanning of scFv specific for KDR.***

[0077] A single chain antibody directed against KDR, scFv p1C11, was isolated from a phage display library constructed from the splenocytes of a mouse immunized with KDR (Zhu, Z. *et al.*, 1998, *Cancer Res.* 58:3209-3214). Female BALB/C mice were given two intraperitoneal (i.p.) injections of 10 µg KDR-AP in 200 µl of RIBI Adjuvant System followed by one i.p. injection without RIBI adjuvant over a period of two months. The mice were also given a subcutaneous (s.c.) injection of 10 µg KDR-AP in 200 µl of RIBI at the time of the first immunization. The mice were boosted i.p. with 20 µg of KDR-AP three days before euthanasia. mRNA was purified from total RNA extracted from splenocytes. Following reverse transcription, cDNAs corresponding to expressed V<sub>L</sub> and V<sub>H</sub> genes were separately amplified. The amplified products were inserted into a vector designed to accept each gene separately or linked to nucleotides encoding a secretion signal sequence and polypeptide linker (*e.g.*, by PCR amplification) and the fused product inserted into a desired vector. *See, e.g.*, Zhu *et al.*, 1998.

[0078] To display the scFv on filamentous phage, antibody V<sub>H</sub> and V<sub>L</sub> domains were joined by a 15 amino acid linker (GGGGS)<sub>3</sub>. The C terminus of this construct was joined to the N terminus of phage protein III with a 15 amino-acid E tag, ending with an amber codon (TAG). The amber codon positioned between the E tag and protein III allows production of scFv in soluble form when transformed into a nonsuppressor host (*e.g.*, HB2151 cells), and phage display via protein III when transformed into a suppressor host (*e.g.*, TG1 cells).

[0079] The scFv-gene III constructs were ligated into the pCANTAB 5E vector. Transformed TG1 cells were plated onto 2YTAG plates (17 g/l tryptone, 10 g/l yeast extract, 5 g/l NaCl, 20 g/l glucose, 100  $\mu$ g/ml ampicillin, 15 g/l Bacto-agar) and incubated. The colonies were scraped into 10 ml of 2YT medium (17 g/l tryptone, 10 g/l yeast extract, 5 g/l NaCl), mixed with 5 ml 50% glycerol and stored at -70°C as the library stock.

[0080] The library stock was grown to log phase, rescued with M13K07 helper phage and amplified overnight in 2YTAK medium (2YT containing 100  $\mu$ g/ml of ampicillin and 50  $\mu$ g/ml of kanamycin) at 30°C. The phage preparation was precipitated in 4% PEG/0.5M NaCl, resuspended in 3% fat-free milk/PBS containing 500  $\mu$ g/ml of alkaline phosphatase (AP) and incubated at 37°C for 1 h to block phage-scFv having specificity for AP scFv and to block other nonspecific binding.

[0081] KDR-AP (10  $\mu$ g/ml) coated Maxisorp Star tubes (Nunc, Denmark) were first blocked with 3% milk/PBS at 37°C for 1 h, and then incubated with the phage preparation at room temperature for 1 h. The tubes were washed 10 times with PBST (PBS containing 0.1% Tween 20), followed by 10 times with PBS. The bound phage were eluted at room temperature for 10 min. with 1 ml of a freshly prepared solution of 100 mM triethylamine. The eluted phage were incubated with 10 ml of mid-log phase TG1 cells at 37°C for 30 min. stationary and 30 min. shaking. The infected TG1 cells were then plated onto 2YTAG plates and incubated overnight at 30°C as provided above for making of the phage stock.

[0082] Successive rounds of the screening procedure were employed to further enrich for displayed scFv having the desired binding specificity. After two or three rounds of panning, individual bacterial colonies were screened individually to identify clones having desired KDR binding characteristics. Identified clones were further tested for blocking of VEGF binding. DNA fingerprinting of clones was used to differentiate unique clones. Representative clones of each digestion pattern were picked and subject to DNA sequencing.

***Human antibodies specific for KDR.***

[0083] A large human Fab phage display library containing  $3.7 \times 10^{10}$  clones (DeHaard et al., *J. Biol. Chem.* 274: 18218-30 (1999)) was used for the selection. The library consists of combinations of PCR-amplified antibody variable light chain genes fused to human constant chain genes ( $\kappa$  and  $\lambda$ ) and variable heavy chain genes fused to DNA encoding the human IgG1 heavy chain C<sub>H</sub>1 domain. Both heavy and light chain constructs are

preceded by a signal sequence - *peI*B for the light chain and gene III signal sequence for the heavy chain. Heavy chain constructs further encode a portion of the gene III protein for phage display, a hexahistidine tag, and an 11 amino-acid-long c-myc tag, followed by an amber codon (TAG). The hexahistidine and c-myc tags can be used for purification or detection. The amber codon allows for phage display using suppressor hosts (such as TG1 cells) or production of Fab fragments in soluble form when transformed into a nonsuppressor host (such as HB2151 cells).

[0084] The library stock was grown to log phase, rescued with M13-KO7 helper phage and amplified overnight in 2YTAK medium (2YT containing 100  $\mu$ g/ml of ampicillin and 50  $\mu$ g/ml of kanamycin) at 30°C. The phage preparation was precipitated in 4% PEG/0.5M NaCl, resuspended in 3% fat-free milk/PBS containing 500  $\mu$ g/ml of AP protein and incubated at 37°C for 1 h to capture phage displaying anti-AP Fab fragments and to block other nonspecific binding.

[0085] KDR-AP (10  $\mu$ g/ml in PBS) coated Maxisorp Star tubes (Nunc, Roskilde, Denmark) were first blocked with 3% milk/PBS at 37°C for 1 h, and then incubated with the phage preparation at RT for 1 h. The tubes were washed 10 times with PBST (PBS containing 0.1% Tween-20) followed by 10 times with PBS. Bound phage were eluted at RT for 10 min with 1 ml of a freshly prepared solution of 100 mM triethylamine (Sigma, St. Louis, MO). The eluted phage were incubated with 10 ml of mid-log phase TG1 cells at 37°C for 30 min stationary and 30 min shaking. The infected TG1 cells were pelleted and plated onto several large 2YTAK plates and incubated overnight at 30°C. All the colonies grown on the plates were scraped into 3 to 5 ml of 2YTA medium, mixed with glycerol (10% final concentration), aliquoted and stored at -70°C. For the next round selection, 100  $\mu$ l of the phage stock was added to 25 ml of 2YTAK medium and grown to mid-log phase. The culture was rescued with M13K07 helper phage, amplified, precipitated, and used for selection followed the procedure described above, with reduced concentrations of KDR-AP immobilized on the immunotube and increased number of washes after the binding process.

[0086] A total of three rounds of selection were performed on immobilized KDR, with varying protein concentrations and number of washings after the initial binding process. After each round selection, 93 clones were randomly picked and tested by phage ELISA for binding to KDR. Seventy out of the 93 clones (75%) picked after the second selection, and

greater than 90% of the recovered clones after the third selection were positive in KDR binding, suggesting a high efficiency of the selection process. DNA segments encoding the Fab from all the 70 binders identified in the second selection were amplified, digested with *Bst*N I, and compared for fingerprint patterns. A total of 42 different patterns were observed, indicating an excellent diversity of the isolated anti-KDR Fab. Cross-reactivity examination demonstrated that 19 out of the 42 antibodies were specific KDR-binders, whereas the rest 23 antibodies bound to both KDR and its murine homologue, Flk-1. Further selection was achieved with a competitive VEGF-binding assay in which the binding of soluble KDR to immobilized VEGF in the presence or absence of the anti-KDR Fab fragments was determined. The assay identified four Fab clones that were capable of blocking the binding between VEGF and KDR. Three were KDR-specific binders and one cross-reacted with Flk-1. DNA fingerprinting and sequencing analysis confirmed that all four KDR/VEGF blocking antibodies were different (Fig. 1A) with unique DNA and amino acid sequences.

[0087] The amino acid sequences for CDR1, CDR2 and CDR3 of  $V_H$  and  $V_L$  for the four clones are given in Table 1.

**Table 1 - CDR sequences of selected KDR-binding human Fabs**

Clone	CDR1	CDR2	CDR3
<b>Light Chain</b>			
D2C6	RASQSVSSYLA (SEQ ID NO:53)	DSSNRAT (SEQ ID NO:54)	LQHNTFPPT (SEQ ID NO:55)
D2H2	RASQGISSRLA (SEQ ID NO:56)	AASSLQT (SEQ ID NO:57)	QQANRFPPT (SEQ ID NO:58)
D1H4	AGTTTDLTYYDLVS (SEQ ID NO:59)	DGNKRPS (SEQ ID NO:60)	NSYVSSRFYV (SEQ ID NO:61)
D1F7	SGSTSNIKTNTAN (SEQ ID NO:62)	NNNQRPS (SEQ ID NO:63)	AAWDDSLNGHWV (SEQ ID NO:64)
<b>Heavy Chain</b>			
D2C6	GFTFSSYSMN (SEQ ID NO:65)	SISSSSYIYYADSVKG (SEQ ID NO:66)	VTDAFDI (SEQ ID NO:67)
D2H2	GFTFSSYSMN	SISSSSYIYYADSVKG	VTDAFDI
D1H4	GFTFSSYSMN	SISSSSYIYYADSVKG	VTDAFDI
D1F7	GGTFSSYAIIS (SEQ ID NO:68)	GGIPIFGTANYAQKFQG (SEQ ID NO:69)	GYDYYDSSGVASPFDY (SEQ ID NO:70)

[0088] Complete sequences for the  $V_H$  and  $V_L$  chains are presented in the Sequence Listing as follows. D1F7:  $V_H$  nucleotide and amino acid sequences in SEQ ID NOS:71 and 72;  $V_L$  nucleotide and amino acid sequences in SEQ ID NOS:73 and 74. D2C6:  $V_H$  nucleotide and amino acid sequences in SEQ ID NOS:75 and 76;  $V_L$  nucleotide and amino acid sequences in SEQ ID NOS:77 and 78. D2H2:  $V_H$  nucleotide and amino acid sequences in SEQ ID NOS:82 and 83;  $V_L$  nucleotide and amino acid sequences in SEQ ID NOS:84 and 85. D1H4:  $V_H$  nucleotide and amino acid sequences in SEQ ID NOS:79 and 76;  $V_L$  nucleotide and amino acid sequences in SEQ ID NOS:80 and 81.

[0089] A second library, consisting of combinations of the single heavy chain of D2C6 with a diverse population of light chains derived from the original library, was created and screened. Ten additional Fabs were identified, designated SA1, SA3, SB10, SB5, SC7, SD2, SD5, SF2, SF7, and 1121. Complete  $V_L$  nucleotide and amino acid sequences are presented in the Sequence Listing as follows. SA1:  $V_L$  nucleotide and amino acid sequences in SEQ ID NOS:86 and 87. SA3:  $V_L$  nucleotide and amino acid sequences in SEQ ID NOS:88 and 89. SB10:  $V_L$  nucleotide and amino acid sequences in SEQ ID NOS:90 and 91. SB5:  $V_L$  nucleotide and amino acid sequences in SEQ ID NOS:92 and 93. SC7:  $V_L$  nucleotide and amino acid sequences in SEQ ID NOS:94 and 95. SD2:  $V_L$  nucleotide and amino acid sequences in SEQ ID NOS:96 and 97. SD5:  $V_L$  nucleotide and amino acid sequences in SEQ ID NOS:98 and 99. SF2:  $V_L$  nucleotide and amino acid sequences in SEQ ID NOS:100 and 101. SF7:  $V_L$  nucleotide and amino acid sequences in SEQ ID NOS:102 and 103. 1121:  $V_L$  nucleotide and amino acid sequences in SEQ ID NOS:104 and 105.

[0090] The  $V_L$  CDR sequences are presented in Table 2.

**Table 2 - Light chain CDR sequences of KDR-binding human Fabs**

Clone	CDR1	CDR2	CDR3
SA1	TGSHSNFGAGTDV (SEQ ID NO:106)	GDSNRPS (SEQ ID NO:107)	QSYDYGLRGWV (SEQ ID NO:108)
SA3	RASQNINNYLN (SEQ ID NO:109)	AASTLQS (SEQ ID NO:110)	QQYSRYPPT (SEQ ID NO:111)
SB10	TGSSTDVGNYNYIS (SEQ ID NO:112)	DVTSRPS (SEQ ID NO:113)	NSYSATDTLV (SEQ ID NO:114)
SB5	TGQSSNIGADYDVH (SEQ ID NO:115)	GHNNRPS (SEQ ID NO:116)	QSYDSSLGGLV (SEQ ID NO:117)
SC7	RASQDISSWLA (SEQ ID NO:118)	AASLLQS (SEQ ID NO:119)	QQADSFPPPT (SEQ ID NO:120)
SD2	RASQSIKRWLA (SEQ ID NO:121)	AASTLQS (SEQ ID NO:122)	QQANSFPPT (SEQ ID NO:123)
SD5	SGRSRNIGAHYEVQ (SEQ ID NO:124)	GDTNRPS (SEQ ID NO:125)	QSYDTSLRGPV (SEQ ID NO:126)
SF2	TGSSSNIGTGYDVH (SEQ ID NO:127)	AYTNRPS (SEQ ID NO:128)	QSFDDSLNGLV (SEQ ID NO:129)
SF7	TGSHSNFGAGTDVH (SEQ ID NO:130)	GDTHRPS (SEQ ID NO:131)	QSYDYGLRGWV (SEQ ID NO:132)
1121	RASQGIDNWLG (SEQ ID NO:133)	DASNLDT (SEQ ID NO:134)	QQAKAFPPPT (SEQ ID NO:135)

***Construction of an anti-KDR x anti-Flt-1 diabody.***

[0091] To construct the diabody, variable domains of scFv p1C11 and scFv 6.12 were used for PCR-directed assembly to create the expression plasmid, pDAB-KF1 (Fig. 1A). First, the following gene fragments were generated by PCR from the V<sub>L</sub> and V<sub>H</sub> domains of p1C11 and MAB6.12: the V<sub>L</sub> domain of p1C11 followed by a segment encoding a 5 amino-acid-linker, GGGGS; the V<sub>H</sub> domain of MAB6.12 preceded by a segment encoding the GGGGS linker; the V<sub>L</sub> domain of MAB6.12 preceded by a segment encoding the *E. coli* heat stable enterotoxin II (stII) signal sequence (Picken, R. N., *et al.*, 1983, *Infect. Immun.* 42:269-275) and followed by a segment encoding the GGGGS linker; and the V<sub>H</sub> domain of p1C11 preceded by a segment encoding the GGGGS linker. Cross-over scFv, pLH-1C11-6.12 and pLH-6.12-1C11, were constructed by annealing of PCR fragments p1C11 V<sub>L</sub> and MAB6.12 V<sub>H</sub>, and MAB6.12 V<sub>L</sub> and p1C11 V<sub>H</sub>, respectively, followed by PCR

amplification to introduce appropriate restriction sites for subsequent cloning. The expression plasmid, pDAB-KF1, for co-secretion of the two cross-over scFv was constructed by ligation of the SfiI/NheI and the NheI/NotI fragments from pLH-1C11-6.12 and pLH-6.12-1C11, respectively, into vector pCANTAB 5E. All sequences encoding the cross-over scFv fragments were verified by DNA sequencing.

***Expression and purification of the diabody.***

[0092] The diabody was prepared from *E. coli* strain HB2151 containing the expression plasmid grown at 30°C in a shaker flask following the procedure previously described (Lu, D. *et al.*, 1999, *J. Immunol. Methods* 230:159-171). A periplasmic extract of the cells was prepared by resuspending the cell pellet in 25 mM Tris (pH 7.5) containing 20% (w/v) sucrose, 200 mM NaCl, 1 mM EDTA and 0.1 mM PMSF, followed by incubation at 4°C with gentle shaking for 1 h. After centrifugation at 15,000 rpm for 15 min, the soluble diabody was purified from the supernatant by anti-E tag affinity chromatography using the RPAS Purification Module (Amersham Pharmacia Biotech). To examine the purity of the diabody preparation, both the *E. coli* periplasmic extract and the purified diabody were electrophoresed in an 18% polyacrylamide gel (Novex, San Diego, CA) and visualized by staining with Colloidal Blue Stain kit (Novex).

***Dual specificity of the diabody to KDR and Flt-1.***

[0093] Two assays were carried out to determine the dual antigen binding capability of the diabody. First, a cross-linking assay was used to investigate whether the diabody is capable of binding both of its target antigens simultaneously. Briefly, the diabody or its parent scFv were first incubated in a 96-well Maxi-sorp microtiter plate (Nunc, Roskilde, Denmark) precoated with Flt-1-Fc fusion protein (1  $\mu$ g/ml x 100  $\mu$ l per well overnight at 4°C) at room temperature (RT) for 1 h. The plate was washed three times with PBS containing 0.1 % Tween (PBST), followed by incubation with KDR-AP fusion protein at RT for additional 1 h. The plate-bound KDR-AP was then quantified by the addition of AP substrate, p-nitrophenyl phosphate (Sigma, St. Louis, MO), followed by reading of the absorbance at 405nm (Lu, D. *et al.*, 1999). In the second, direct binding assay, various amounts of diabody or scFv were added to KDR or Flt-1 coated 96-well plates and incubated at RT for 1 h, after which the plates were washed 3 times with PBST. The plates were then incubated at RT for 1 h with 100  $\mu$ l of an anti-E tag antibody-HRP conjugate (Amersham

Pharmacia Biotech). The plates were washed, peroxidase substrate added, and the absorbance at 450 nm read following the procedure described previously (Lu, D. *et al.*, 1999).

***VEGF/KDR, VEGF/Flt-1, and PIgf/Flt-1 blocking assays.***

[0094] The assays followed previously described protocols (Zhu, Z. *et al.*, 1998; Lu, D. *et al.*, 1999). Briefly, various amounts of the diabody or scFv were mixed with a fixed amount of KDR-AP (100 ng) or Flt-1-Fc fusion protein (50 ng) and incubated at RT for 1 h. The mixture were then transferred to 96-well microtiter plates precoated with VEGF<sub>165</sub> (200 ng/well) or PIgf (200 ng/well) and incubated at RT for an additional 2 h, after which the plates were washed 5 times with PBS. For the KDR-AP assay, the substrate for AP was added, followed by reading of the absorbance at 405nm to quantify the plate-bound KDR-AP. For the Flt-1-Fc assay, the plate was incubated with a mouse anti-human Fc-HRP conjugate to quantify the plate-bound Flt-1-Fc. The IC<sub>50</sub>, *i.e.*, the antibody concentration required for 50% inhibition of KDR or Flt-1 binding to VEGF or PIgf, was then calculated.

***Analysis of binding kinetics.***

[0095] The binding kinetics of the diabody and its parent scFv to KDR and Flt-1 were measured using a BIACore biosensor (Pharmacia Biosensor). KDR-AP or Flt-1-Fc fusion protein was immobilized onto a sensor chip and soluble antibodies were injected at concentrations ranging from 1.5 nM to 100 nM. Sensograms were obtained at each concentration and were analyzed with, BIA Evaluation 2.0, a program to determine the rate constants *kon* and *koff*. The affinity constant, *Kd*, was calculated from the ratio of rate constants *koff/kon*.

***Anti-mitogenic assay.***

[0096] HUVEC (5 x 10<sup>3</sup> cells/well) were plated onto 96-well tissue culture plates (Wallach, Inc., Gaithersburg, MD) in 200  $\mu$ l of EBM-2 medium without VEGF, basic fibroblast growth factor or epidermal growth factor (EGF) and incubated at 37°C for 72 h. Various amounts of the antibodies were added to duplicate wells and pre-incubated at 37°C for 1 h, after which VEGF165 was added to a final concentration of 16 ng/ml. After 18 h of incubation, 0.25  $\mu$ Ci of [<sup>3</sup>H]-TdR (Amersham) was added to each well and incubated for an additional 4 h. The cells were washed once with PBS, trypsinized and harvested onto a glass fiber filter (Printed Filtermat A, Wallach) with a cell harvester (Harvester 96, MACH III M, TOMTEC, Orange, CT). The membrane was washed three times with H<sub>2</sub>O and air-dried.

Scintillation fluid was added and DNA incorporated radioactivity was determined on a scintillation counter (Wallach, Model 1450 Microbeta Liquid Scintillation Counter).

***Leukemia migration assay.***

[0097] HL60 and HEL cells were washed three times with serum-free plain RPMI 1640 medium and suspended in the medium at  $1 \times 10^6$ /ml. Aliquots of 100  $\mu$ l cell suspension were added to either 3- $\mu$ m-pore transwell inserts (for HL60 cells), or 8- $\mu$ m-pore transwell inserts (for HEL cells) (Costar®, Corning Incorporated, Corning, NY) and incubated with the antibodies for 30 min at 37°C. The inserts were then placed into the wells of 24-well plates containing 0.5 ml of serum-free RPMI 1640 with or without VEGF165. The migration was carried out at 37°C, 5% CO<sub>2</sub> for 16-18 h for HL60 cells, or for 4 h for HEL cells. Migrated cells were collected from the lower compartments and counted with a Coulter counter (Model Z1, Coulter Electronics Ltd., Luton, England).

**EXAMPLE 2: anti-KDR x anti-Flt-1 diabody**

***Diabody structure.***

[0098] An anti-KDR x anti-Flt-1 diabody made according to Example I was purified and analyzed by SDS-PAGE. The two component polypeptides were resolved under the electrophoretic conditions and gave rise to two major bands with mobility close to that anticipated (Fig. 1B); the lower band represents the first polypeptide (m.w., 25179.6 daltons), and the upper band correlates with the second polypeptide with E-tag (m.w., 26693.8 daltons) (Fig. 1A).

***Dual specificity.***

[0099] A cross-linking assay to investigate whether the anti-KDR x anti-Flt-1 diabody was capable of simultaneously binding to both of its target antigens. To test the capability of the Flt-1-bound diabody to capture soluble KDR, the diabody was first allowed to bind to immobilized Flt-1, followed by incubation with KDR-AP. As shown in Fig. 2A, the diabody, but not the parent monospecific scFv, efficiently cross-linked the soluble KDR to the immobilized Flt-1, as demonstrated by the plate-bound AP activity.

[0100] The antigen binding efficiency of the diabody was determined on immobilized KDR and Flt-1. The diabody bound as efficiently as the parent scFv p1C11 to KDR (Fig. 2B). Binding the diabody to Flt-1 was slightly reduced, compared to the parent scFv 6.12 (Fig. 2C). As expected, the KDR-specific scFv p1C11 did not bind to Flt-1 (Fig.

2B), and Flt-1-specific scFv 6.12 did not bind to KDR (Fig. 2C). Data shown in Fig. 2 represent the mean  $\pm$  SD of triplicate samples.

[0101] The binding kinetics of the diabody to KDR and Flt-1 were determined by surface plasmon resonance using a BIACore instrument (Table 3) and are consistent with the ELISA results of Fig. 2. The diabody binds to KDR with kinetics similar to its parent scFv p1C11 with a Kd of 1.4 nM. The binding affinity of the diabody to Flt-1 was moderately reduced compared to scFv 6.12, mainly due to a slower on-rate of the diabody (Table 3).

**Table 3: Binding kinetics of the anti-KDR x anti-Flt-1 diabody as determined by BIACore**

Antibody	KDR			Flt-1		
	<i>kon</i> ( $10^4$ M $^{-1}$ S $^{-1}$ )	<i>koff</i> ( $10^4$ S $^{-1}$ )	Kd (nM)	<i>kon</i> ( $10^4$ M $^{-1}$ S $^{-1}$ )	<i>koff</i> ( $10^4$ S $^{-1}$ )	Kd (nM)
ScFv p1C11	$7.42 \pm 0.88^a$	$1.21 \pm 0.36$	$1.68 \pm 0.66$	ND	ND	ND
ScFv 6.12	ND	ND	ND	$24.1 \pm 0.1$	$23.6 \pm 4.8$	$9.8 \pm 1.98$
Diabody	$6.24 \pm 0.76$	$0.87 \pm 0.14$	$1.40 \pm 0.27$	$7.73 \pm 1.15$	$23.4 \pm 0.92$	$30.7 \pm 5.7$

[0102] Fig. 3A shows that the diabody blocks KDR from binding to immobilized VEGF, in a dose-dependent manner as efficiently as scFv p1C11, with an IC<sub>50</sub> of approximately 2 nM. The diabody also blocks Flt-1 from binding to VEGF with an IC<sub>50</sub> of about 15 nM, which is about 10-fold less potent than the parent scFv 6.12 (Fig. 3B). Further, the diabody blocks P1GF, a Flt-1-specific ligand, from binding to immobilized Flt-1 with an IC<sub>50</sub> of approximately 4 nM (Fig. 3C). As expected, scFv p1C11 had no effects on Flt-1/VEGF and Flt-1/P1GF interaction, whereas scFv 6.12 had no effects on KDR/VEGF interaction. Data shown represent the mean  $\pm$  SD of triplicate samples.

### EXAMPLE 3: Biological activity

#### *Inhibition of VEGF-induced migration of leukemia cells and mitogenesis of HUVEC.*

[0103] The diabody was first tested for its activity in inhibiting VEGF and P1GF-induced cell migration. Both VEGF and P1GF induced migration of human leukemia cells, HL60 and HEL, in a dose-dependent manner (Fig. 4A and 4D). scFv p1C11 and scFv 6.12 effectively inhibited VEGF and P1GF-induced cell migration (Fig. 4B, 4C, 4E and 4F). Data shown are representative of at least three separate experiments and represent the mean  $\pm$

SD of triplicate determinations. The two scFv showed a different efficacy pattern: scFv p1C11 is a stronger inhibitor of VEGF-induced cell migration, whereas scFv 6.12 is slightly more potent in inhibiting PIGF-induced cell migration. In contrast, the diabody is equally effective in blocking cell migration induced by both VEGF and PI GF. Combination of both scFv p1C11 and scFv 6.12, either as a simple mixture or in the diabody format, demonstrated a more potent inhibitory effect than either scFv alone. It is noteworthy that neither scFv p1C11 nor scFv 6.12 alone was able to completely inhibit VEGF or PI GF-induced cell migration, even at the highest antibody concentration tested (i.e., 200 nM). In contrast, combination of scFv p1C11 and scFv 6.12, either as a mixture or a diabody, completely abolished cell migration at an antibody concentration of 200 nM. A Fab fragment of C225, an antibody directed against epidermal growth factor receptor, did not show significant inhibition of cell migration in this assay.

[0104] The VEGF-neutralizing activity of the bifunctional diabody was further determined using a HUVEC mitogenic assay. Data shown are the means of duplicates and are the representative of at least three separate experiments. As previously seen, scFv p1C11 effectively inhibited VEGF-stimulated HUVEC mitogenesis (measured by [<sup>3</sup>H]-TdR incorporation) in a dose-dependent manner with an IC<sub>50</sub> of approximately 2 nM. Anti-Flt-1 scFv 6.12 showed a very weak anti-mitogenic effect in this assay. The bifunctional diabody demonstrated a much stronger inhibitory effect than either scFv p1C11 and scFv 6.12 at every antibody concentration tested, with an IC<sub>50</sub> of approximately 0.5 nM (Fig. 5). Data shown are the means of duplicates and are the representative of at least three separate experiments.

What is claimed is:

1. An antibody having a first antigen binding site specific for a first VEGF receptor and a second antigen binding site specific for a second VEGF receptor.
2. The antibody of Claim 1 wherein the first and second VEGF receptors are mammalian.
3. The antibody of Claim 1 wherein the first and second VEGF receptors are human.
4. The antibody of Claim 3 wherein the first and second VEGF receptors are selected from the group consisting of KDR, Flt-1 and Flt-4.
5. The antibody of Claim 3 wherein the first VEGF receptor is KDR and the second VEGF receptor is Flt-1.
6. The antibody of Claim 3 wherein the first VEGF receptor is KDR and the amino acid sequences of the complementarity determining regions (CDRs) of the first antigen binding site comprise:
  - SEQ ID NO: 1 at CDRH1;
  - SEQ ID NO: 2 at CDRH2;
  - SEQ ID NO: 3 at CDRH3;
  - SEQ ID NO: 4 at CDRL1;
  - SEQ ID NO: 5 at CDRL2; and
  - SEQ ID NO: 6 at CDRL3.
7. The antibody of Claim 3 wherein the first VEGF receptor is KDR and the amino acid sequences of the variable domains of the first antigen binding site comprise:
  - SEQ ID NO: 7 for the heavy-chain variable domain ( $V_H$ ); and
  - SEQ ID NO: 8 for the light-chain variable domain ( $V_L$ ).

8. The antibody of Claim 3 wherein the first VEGF receptor is KDR and the nucleotide sequences of the complementarity determining regions (CDRs) of the first antigen binding site comprise:

SEQ ID NO: 9 for CDRH1;  
SEQ ID NO: 10 for CDRH2;  
SEQ ID NO: 11 for CDRH3;  
SEQ ID NO: 12 for CDRL1;  
SEQ ID NO: 13 for CDRL2; and  
SEQ ID NO: 14 for CDRL3.

9. The antibody of Claim 3 wherein the first VEGF receptor is KDR and the nucleotide sequences of the variable domains of the first antigen binding site comprise:

SEQ ID NO: 15 for the heavy-chain variable domain ( $V_H$ ); and  
SEQ ID NO: 16 for the light-chain variable domain ( $V_L$ ).

10. The antibody of Claim 3 wherein the first VEGF receptor is KDR and the amino acid sequences of the complementarity determining regions (CDRs) of the first antigen binding site comprise:

SEQ ID NO: 1 for CDRH1;  
SEQ ID NO: 21 for CDRH2;  
SEQ ID NO: 3 for CDRH3;  
SEQ ID NO: 4 for CDRL1;  
SEQ ID NO: 5 for CDRL2; and  
SEQ ID NO: 6 for CDRL3.

11. The antibody of Claim 3 wherein the first VEGF receptor is KDR and the amino acid sequences of the variable domains of the first antigen binding site comprise:

SEQ ID NO: 22 for the heavy-chain variable domain ( $V_H$ ); and  
SEQ ID NO: 23 for the light-chain variable domain ( $V_L$ ).

12. The antibody of Claim 3 wherein the first VEGF receptor is KDR and the nucleotide sequences of the complementarity determining regions (CDRs) of the first antigen binding site comprise:

SEQ ID NO: 9 for CDRH1;  
SEQ ID NO: 24 for CDRH2;  
SEQ ID NO: 11 for CDRH3;  
SEQ ID NO: 12 for CDRL1;  
SEQ ID NO: 13 for CDRL2; and  
SEQ ID NO: 14 for CDRL3.

13. The antibody of Claim 3 wherein the first VEGF receptor is KDR and the nucleotide sequences of the variable domains of the first antigen binding site comprise:

SEQ ID NO: 25 for the heavy-chain variable domain (V<sub>H</sub>); and  
SEQ ID NO: 26 for the light-chain variable domain (V<sub>L</sub>).

14. The antibody of Claim 3 wherein the first VEGF receptor is KDR and the first antigen binding site comprises a set of amino acid sequences at CDRL1, CDRL2, CDRL3, CDRH1, CDRH2, and CDRH3, the set selected from the group consisting of the set of SEQ ID NOS:53, 54, 55, 65, 66, and 67, the set of SEQ ID NOS:56, 57, 58, 65, 66 and 67, the set of SEQ ID NOS:59, 60, 61, 65, 66, and 67, and the set of SEQ ID NOS:62, 63, 64, 68, 69 and 70.

15. The antibody of Claim 3 wherein the first VEGF receptor is KDR and the first binding domain comprises a pair of V<sub>H</sub> and V<sub>L</sub> domains, the pairs selected from the group consisting of SEQ ID NOS:72 and 74, SEQ ID NOS:76 and 78, SEQ ID NOS:76 and 81, and SEQ ID NOS:83 and 85.

16. The antibody of Claim 3 wherein the first VEGF receptor is KDR and the first antigen binding site comprises the set of amino acid sequences CDH1, CDRH2, and CDRH3 given by SEQ ID NOS: 65, 66, and 67, respectively, and a set of amino acid sequences at CDRL1, CDRL2, CDRL3 selected from the group consisting of the set of SEQ ID NOS:106,

107, and 108, the set of SEQ ID NOS:109, 110, and 111, the set of SEQ ID NOS:112, 113, and 114, the set of SEQ ID NOS:115, 116, and 117, the set of SEQ ID NOS:118, 119, and 120, the set of SEQ ID NOS:121, 122, and 123, the set of SEQ ID NOS:124, 125, and 126, the set of SEQ ID NOS:127, 128, and 129, the set of SEQ ID NOS:130, 131, and 132, and the set of SEQ ID NOS:133, 134, and 135.

17. The antibody of Claim 3 wherein the first VEGF receptor is KDR, the  $V_H$  domain of first binding domain comprises SEQ ID NO:76, and the  $V_L$  domain of the first binding domain comprises a sequence selected from the group consisting of SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, and SEQ ID NO:105.

18. The antibody of any one of Claims 6 to 17 wherein the second VEGF receptor is Flt-1 and the second antigen binding site comprises the heavy chain and light chain variable domains of Mab 6.12 (ATCC No. PTA-3344).

19. The antibody of Claim 3 wherein the first VEGF receptor is Flt-1 and the amino acid sequences of the complementarity determining regions (CDRs) of the first antigen binding site comprise:

SEQ ID NO: 35 at CDRH1;  
SEQ ID NO: 36 at CDRH2;  
SEQ ID NO: 37 at CDRH3;  
SEQ ID NO: 38 at CDRL1;  
SEQ ID NO: 39 at CDRL2; and  
SEQ ID NO: 40 at CDRL3.

20. The antibody of Claim 3 wherein the first VEGF receptor is Flt-1 and the amino acid sequences of the variable domains of the first antigen binding site comprise:

SEQ ID NO: 41 for the heavy-chain variable domain ( $V_H$ ); and  
SEQ ID NO: 42 for the light-chain variable domain ( $V_L$ ).

21. The antibody of Claim 3 wherein the first VEGF receptor is Flt-1 and the nucleotide sequences of the complementarity determining regions (CDRs) of the first antigen binding site comprise:

SEQ ID NO: 43 for CDRH1;  
SEQ ID NO: 44 for CDRH2;  
SEQ ID NO: 45 for CDRH3;  
SEQ ID NO: 46 for CDRL1;  
SEQ ID NO: 47 for CDRL2; and  
SEQ ID NO: 48 for CDRL3.

22. The antibody of Claim 3 wherein the first VEGF receptor is Flt-1 and the nucleotide sequences of the variable domains of the first antigen binding site comprise:

SEQ ID NO: 49 for the heavy-chain variable domain ( $V_H$ ); and  
SEQ ID NO: 50 for the light-chain variable domain ( $V_L$ ).

23. The antibody of Claim 3 wherein the first VEGF receptor is Flt-1 and the first antigen binding site comprises the heavy chain and light chain variable domains of Mab 6.12 (ATCC No. PTA-3344).

24. An antibody that binds specifically to an extracellular domain of a first VEGF receptor and an extracellular domain of a second VEGF receptor, wherein binding of the antibody to the first or the second VEGF receptor neutralizes activation of that VEGF receptor.

25. The antibody of Claim 24 which blocks binding of VEGF.

26. The antibody of Claim 24 which blocks receptor homodimerization.

27. The antibody of Claim 24 which blocks receptor heterodimerization.

28. The antibody of Claim 24 wherein the first and second VEGF receptors are selected from the group consisting of KDR, Flt-1 and Flt-4.

29. The antibody of Claim 24 wherein the first VEGR receptor is KDR and the second VEGR receptor is Flt-1.

30. An antibody that binds specifically to an extracellular domain of a first VEGF receptor and an extracellular domain of a second VEGF receptor and reduces tumor growth.

31. The antibody of Claim 29 wherein the first and second VEGF receptors are selected from the group consisting of KDR, Flt-1 and Flt-4.

32. The antibody of Claim 29 wherein the first VEGR receptor is KDR and the second VEGR receptor is Flt-1.

33. A antibody that binds specifically to an extracellular domain of a first VEGF receptor and an extracellular domain of a second VEGF receptor and inhibits angiogenesis.

34. The antibody of Claim 32 wherein the first and second VEGF receptors are selected from the group consisting of KDR, Flt-1 and Flt-4.

35. The antibody of Claim 32 wherein the first VEGR receptor is KDR and the second VEGR receptor is Flt-1.

36. A method for making an antibody having a first antigen binding site comprising a first immunoglobulin heavy chain variable domain and a first immunoglobulin light chain variable domain that specifically binds to an extracellular domain of a first VEGF receptor, and a second antigen binding site comprising a second immunoglobulin heavy chain variable domain and a second immunoglobulin light chain variable domain that specifically binds to an extracellular domain of a second VEGF receptor, which comprises

a) coexpressing in a host cell

a recombinant DNA construct encoding a first polypeptide having the first immunoglobulin heavy chain variable domain located to the N terminus of the second immunoglobulin light chain variable domain, and

a recombinant DNA construct encoding a second polypeptide having the second immunoglobulin heavy chain variable domain located to the N terminus of the first immunoglobulin light chain variable domain,

for a time and in a manner sufficient to allow expression of the polypeptides and formation of the antibody; and

b) recovering the antibody.

37. The method of Claim 35 wherein the constructs are on the same DNA expression vector.

38. The method of Claim 35 wherein the constructs are on different DNA expression vectors.



39. The method of Claim 35 wherein the host cell is a bacterial cell, a yeast cell or a mammalian cell.

40. The method of Claim 35 wherein the antibody is secreted from the host cell.


41. A method for neutralizing activation of a first VEGF receptor and a second VEGF receptor in a cell which comprises treating a cell with an antibody having a first antigen binding site specific for the first VEGF receptor and a second binding site specific for the second VEGF receptor in an amount sufficient to neutralize activation of the receptors.


42. A method for reducing tumor growth in a mammal in need thereof comprising treating the mammal with an antibody having a first antigen binding site specific for the first VEGF receptor and a second binding site specific for the second VEGF receptor in an amount effective to reduce tumor growth.


43. A method for inhibiting angiogenesis in a mammal in need thereof comprising treating the mammal with a bispecific antibody having a first antigen binding site specific for the first VEGF receptor and a second binding site specific for the second VEGF receptor in an amount effective to inhibit angiogenesis.


**Figure 1.****A****B**

1/5

**Figure 2.**

**Figure 3.**

**Figure 4.**

**Figure 5.**

## SEQUENCE LISTING

<110> Zhu, Zhenping

<120> Bispecific Antibodies That Bind to VEGF Receptors

<130> 11245/485762

<140> filed concurrently herewith

<141> 2002-12-24

<150> PCT/US02/20332

<151> 2002-06-26

<150> US 60/301,299

<151> 2002-06-26

<160> 137

<170> WordPerfect 8.0 for Windows

<210> 1

<211> 10

<212> PRT

<213> Mouse

<400> 1

Gly Phe Asn Ile Lys Asp Phe Tyr Met His  
1 5 10

<210> 2

<211> 17

<212> PRT

<213> Mouse

<400> 2

Trp Ile Asp Pro Glu Asn Gly Asp Ser Gly Tyr Ala Pro Lys Phe Gln  
1 5 10 15

Gly

17

<210> 3

<211> 8

<212> PRT

<213> Mouse

<400> 3

Tyr Tyr Gly Asp Tyr Glu Gly Tyr  
1 5

<210> 4

<211> 10

<212> PRT

<213> Mouse

<400> 4

Ser Ala Ser Ser Ser Val Ser Tyr Met His  
1 5 10

<210> 5  
<211> 7  
<212> PRT  
<213> Mouse

<400> 5

Ser Thr Ser Asn Leu Ala Ser  
1 5

<210> 6  
<211> 9  
<212> PRT  
<213> Mouse

<400> 6

Gln Gln Arg Ser Ser Tyr Pro Phe Thr  
1 5

<210> 7  
<211> 117  
<212> PRT  
<213> Mouse

<400> 7

Gln Val Lys Leu Gln Gln Ser Gly Ala Glu Leu Val Gly Ser Gly Ala  
1 5 10 15

Ser Val Lys Leu Ser Cys Thr Thr Ser Gly Phe Asn Ile Lys Asp Phe  
20 25 30

Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile  
35 40 45

Gly Trp Ile Asp Pro Glu Asn Gly Asp Ser Gly Tyr Ala Pro Lys Phe  
50 55 60

Gln Gly Lys Ala Thr Met Thr Ala Asp Ser Ser Ser Asn Thr Ala Tyr  
65 70 75 80

Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Asn Ala Tyr Tyr Gly Asp Tyr Glu Gly Tyr Trp Gly Gln Gly Thr Thr  
100 105 110

Val Thr Val Ser Ser  
115

<210> 8  
<211> 108  
<212> PRT  
<213> Mouse

<400> 8

Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly  
1 5 10 15

Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met  
20 25 30

His Trp Phe Gln Gln Lys Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr  
35 40 45

Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser  
50 55 60

Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu  
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Phe Thr  
85 90 95

Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg Ala  
100 105

<210> 9

<211> 30

<212> DNA

<213> Mouse

<400> 9

ggc ttc aac att aaa gac ttc tat atg cac 30  
Gly Phe Asn Ile Lys Asp Phe Tyr Met His  
1 5 10

<210> 10

<211> 51

<212> DNA

<213> Mouse

<400> 10

tgg att gat cct gag aat ggt gat tct ggt tat gcc ccg aag ttc cag 48  
Trp Ile Asp Pro Glu Asn Gly Asp Ser Gly Tyr Ala Pro Lys Phe Gln  
1 5 10 15

ggc

Gly

17

51

<210> 11

<211> 24

<212> DNA

<213> Mouse

<400> 11

tac tat ggt gac tac gaa ggc tac 24  
Tyr Tyr Gly Asp Tyr Glu Gly Tyr  
1 5

<210> 12

<211> 30

<212> DNA

<213> Mouse

<400> 12

agt gcc agc tca agt ta a gt tac atg cac  
 Ser Ala Ser Ser Ser Val Ser Tyr Met His  
 1 5 10

30

<210> 13  
 <211> 21  
 <212> DNA  
 <213> Mouse

&lt;400&gt; 13

agc aca tcc aac ctg gct tct  
 Ser Thr Ser Asn Leu Ala Ser  
 1 5

21

<210> 14  
 <211> 27  
 <212> DNA  
 <213> Mouse

&lt;400&gt; 14

cag caa agg agt agt tac cca ttc acg  
 Gln Gln Arg Ser Ser Tyr Pro Phe Thr  
 1 5

27

<210> 15  
 <211> 351  
 <212> DNA  
 <213> Mouse

&lt;400&gt; 15

cag gtc aag ctg cag cag tct ggg gca gag ctt gtg ggg tca ggg gcc  
 Gln Val Lys Leu Gln Gln Ser Gly Ala Glu Leu Val Gly Ser Gly Ala  
 1 5 10 15

48

tca gtc aaa ttg tcc tgc aca act tct ggc ttc aac att aaa gac ttc  
 Ser Val Lys Leu Ser Cys Thr Thr Ser Gly Phe Asn Ile Lys Asp Phe  
 20 25 30

96

tat atg cac tgg gtg aag cag agg cct gaa cag ggc ctg gag tgg att  
 Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile  
 35 40 45

144

gga tgg att gat cct gag aat ggt gat tct ggt tat gcc ccg aag ttc  
 Gly Trp Ile Asp Pro Glu Asn Gly Asp Ser Gly Tyr Ala Pro Lys Phe  
 50 55 60

192

cag ggc aag gcc acc atg act gca gac tca tcc tcc aac aca gcc tac  
 Gln Gly Lys Ala Thr Met Thr Ala Asp Ser Ser Ser Asn Thr Ala Tyr  
 65 70 75 80

240

ctg cag ctc agc agc ctg aca tct gag gac act gcc gtc tat tac tgt  
 Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

288

aat gca tac tat ggt gac tac gaa ggc tac tgg ggc caa ggg acc acg  
 Asn Ala Tyr Tyr Gly Asp Tyr Glu Gly Tyr Trp Gly Gln Gly Thr Thr  
 100 105 110

336

gtc acc gtc tcc tc  
 Val Thr Val Ser Ser  
 115

<210> 16  
 <211> 324  
 <212> DNA  
 <213> Mouse

<400> 16

gac atc gag ctc act cag tct cca gca atc atg tct gca tct cca ggg 48  
 Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly  
 1 5 10 15

gag aag gtc acc ata acc tgc agt gcc agc tca agt gta agt tac atg 96  
 Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met  
 20 25 30

cac tgg ttc cag cag aag cca ggc act tct ccc aaa ctc tgg att tat 144  
 His Trp Phe Gln Gln Lys Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr  
 35 40 45

agc aca tcc aac ctg gct tct gga gtc cct gct cgc ttc agt ggc agt 192  
 Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser  
 50 55 60

gga tct ggg acc tct tac tct ctc aca atc agc cga atg gag gct gaa 240  
 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu  
 65 70 75 80

gat gct gcc act tat tac tgc cag caa agg agt agt tac cca ttc acg 288  
 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Phe Thr  
 85 90 95

ttc ggc tcg ggg acc aag ctg gaa ata aaa cgg gcg 324  
 Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg Ala  
 100 105

<210> 17  
 <211> 15  
 <212> PRT  
 <213> Mouse

<400> 17

Gly Gly Gly Ser Gly Gly Ser Gly Gly Gly Ser  
 1 5 10 15

<210> 18  
 <211> 45  
 <212> DNA  
 <213> Mouse

<400> 18

gggtggaggcg gttcaggcg aggtggctct ggccgtggcg gatcg 45

<210> 19  
 <211> 10  
 <212> PRT

<213> Mouse

<400> 19

Gly Gly Gly Gly Ser Gly Gly Gly Ser  
1 5 10

<210> 20

<211> 15

<212> DNA

<213> Mouse

<400> 20

ggtgtggaggcg gttca

15

<210> 21

<211> 17

<212> PRT

<213> Mouse

<400> 21

Trp Ile Asp Pro Glu Asn Gly Asp Ser Asp Tyr Ala Pro Lys Phe Gln  
1 5 10 15

Gly  
17

<210> 22

<211> 117

<212> PRT

<213> Mouse

<400> 22

Gln Val Lys Leu Gln Gln Ser Gly Ala Glu Leu Val Gly Ser Gly Ala  
1 5 10 15

Ser Val Lys Leu Ser Cys Thr Thr Ser Gly Phe Asn Ile Lys Asp Phe  
20 25 30

Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile  
35 40 45

Gly Trp Ile Asp Pro Glu Asn Gly Asp Ser Asp Tyr Ala Pro Lys Phe  
50 55 60

Gln Gly Lys Ala Thr Met Thr Ala Asp Ser Ser Ser Asn Thr Ala Tyr  
65 70 75 80

Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Asn Ala Tyr Tyr Gly Asp Tyr Glu Gly Tyr Trp Gly Gln Gly Thr Thr  
100 105 110

Val Thr Val Ser Ser  
115

<210> 23

<211> 106  
 <212> PRT  
 <213> Mouse

<400> 23

Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly  
 1 5 10 15

Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met  
 20 25 30

His Trp Phe Gln Gln Lys Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr  
 35 40 45

Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser  
 50 55 60

Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu  
 65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Phe Thr  
 85 90 95

Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys  
 100 105

<210> 24  
 <211> 51  
 <212> DNA  
 <213> Mouse

<400> 24

tggattgatc ctgagaatgg tgattctgat tatgccccga agttccaggg c 51

<210> 25  
 <211> 351  
 <212> DNA  
 <213> Mouse

<400> 25

cag gtc aag ctg cag cag tct ggg gca gag ctt gtg ggg tca ggg gcc 48  
 Gln Val Lys Leu Gln Gln Ser Gly Ala Glu Leu Val Gly Ser Gly Ala  
 1 5 10 15

tca gtc aaa ttg tcc tgc aca act tct ggc ttc aac att aaa gac ttc 96  
 Ser Val Lys Leu Ser Cys Thr Thr Ser Gly Phe Asn Ile Lys Asp Phe  
 20 25 30

tat atg cac tgg gtg aag cag agg cct gaa cag ggc ctg gag tgg att 144  
 Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile  
 35 40 45

gga tgg att gat cct gag aat ggt gat tct gat tat gcc ccg aag ttc 192  
 Gly Trp Ile Asp Pro Glu Asn Gly Asp Ser Asp Tyr Ala Pro Lys Phe  
 50 55 60

cag ggc aag gcc acc atg act gca gac tca tcc tcc aac aca gcc tac 240  
 Gln Gly Lys Ala Thr Met Thr Ala Asp Ser Ser Ser Asn Thr Ala Tyr  
 65 70 75 80

ctg cag ctc agc agc 85 g aca tct gag gac act gcc gtc ta 288  
 Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
 90 95

aat gca tac tat ggt gac tac gaa ggc tac tgg ggc caa ggg acc acg 336  
 Asn Ala Tyr Tyr Gly Asp Tyr Glu Gly Tyr Trp Gly Gln Gly Thr Thr  
 100 105 110

gtc acc gtc tcc tca 351  
 Val Thr Val Ser Ser  
 115

<210> 26  
 <211> 318  
 <212> DNA  
 <213> Mouse

<400> 26

gac atc gag ctc act cag tct cca gca atc atg tct gca tct cca ggg 48  
 Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly  
 1 5 10 15

gag aag gtc acc ata acc tgc agt gcc agc tca agt gta agt tac atg 96  
 Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Val Ser Tyr Met  
 20 25 30

cac tgg ttc cag cag aag cca ggc act tct ccc aaa ctc tgg att tat 144  
 His Trp Phe Gln Gln Lys Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr  
 35 40 45

agc aca tcc aac ctg gct tct gga gtc cct gct cgc ttc agt ggc agt 192  
 Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser  
 50 55 60

gga tct ggg acc tct tac tct ctc aca atc agc cga atg gag gct gaa 240  
 Gly Ser Gly Thr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu  
 65 70 75 80

gat gct gcc act tat tac tgc cag caa agg agt agt tac cca ttc acg 288  
 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Phe Thr  
 85 90 95

ttc ggc tcg ggg acc aag ctg gaa ata aaa 318  
 Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys  
 100 105

<210> 27  
 <211> 240  
 <212> PRT  
 <213> Mouse

<400> 27

Gln Val Lys Leu Gln Gln Ser Gly Ala Glu Leu Val Gly Ser Gly Ala  
 1 5 10 15

Ser Val Lys Leu Ser Cys Thr Thr Ser Gly Phe Asn Ile Lys Asp Phe  
 20 25 30

Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile  
 35 40 45

Gly Trp Ile Asp Pro ~~Ala~~ Asn Gly Asp Ser Gly Tyr Ala Pro Lys Phe  
 50 55 60

Gln Gly Lys Ala Thr Met Thr Ala Asp Ser Ser Ser Asn Thr Ala Tyr  
 65 70 75 80

Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Asn Ala Tyr Tyr Gly Asp Tyr Glu Gly Tyr Trp Gly Gln Gly Thr Thr  
 100 105 110

Val Thr Val Ser Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly  
 115 120 125

Gly Gly Gly Ser Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met Ser  
 130 135 140

Ala Ser Pro Gly Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser  
 145 150 155 160

Val Ser Tyr Met His Trp Phe Gln Gln Lys Pro Gly Thr Ser Pro Lys  
 165 170 175

Leu Trp Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg  
 180 185 190

Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg  
 195 200 205

Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser  
 210 215 220

Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg Ala  
 225 230 235 240

<210> 28  
<211> 238  
<212> PRT  
<213> Mouse

<400> 28

Gln	Val	Lys	Leu	Gln	Gln	Ser	Gly	Ala	Glu	Leu	Val	Gly	Ser	Gly	Ala
1				5					10					15	
Ser	Val	Lys	Leu	Ser	Cys	Thr	Thr	Ser	Gly	Phe	Asn	Ile	Lys	Asp	Phe
					20				25				30		
Tyr	Met	His	Trp	Val	Lys	Gln	Arg	Pro	Glu	Gln	Gly	Leu	Glu	Trp	Ile
					35			40				45			
Gly	Trp	Ile	Asp	Pro	Glu	Asn	Gly	Asp	Ser	Asp	Tyr	Ala	Pro	Lys	Phe
					50			55			60				
Gln	Gly	Lys	Ala	Thr	Met	Thr	Ala	Asp	Ser	Ser	Ser	Asn	Thr	Ala	Tyr
					65			70			75			80	
Leu	Gln	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
					85				90				95		
Asn	Ala	Tyr	Tyr	Gly	Asp	Tyr	Glu	Gly	Tyr	Trp	Gly	Gln	Gly	Thr	Thr
					100			105				110			

Val Thr Val Ser Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly  
115 120 125

Gly Gly Gly Ser Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met Ser  
130 135 140

Ala Ser Pro Gly Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser  
145 150 155 160

Val Ser Tyr Met His Trp Phe Gln Gln Lys Pro Gly Thr Ser Pro Lys  
165 170 175

Leu Trp Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg  
180 185 190

Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg  
195 200 205

Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser  
210 215 220

Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys  
225 230 235

<210> 29  
<211> 43  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Synthetic primer

<400> 29

ctagtagcaa ctgccacccgg cgtacattca caggtcaagc tgc 43

<210> 30  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Synthetic primer

<400> 30

tcgaaggatc actcaccttt tatttccagc 30

<210> 31  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Synthetic primer

<400> 31

ggtaaaaagc ttatggggat ggtcatgtat catcctttt ctagtagcaa ct 52

<210> 32  
<211> 36  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Signal

<400> 32

tcgatctaga aggatccact cacgtttat ttccag

36

<210> 33  
<211> 19  
<212> PRT  
<213> Artificial Sequence

<220>

<223> leader peptide

<400> 33

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly  
5 10 15

Val His Ser  
19

<210> 34  
<211> 32  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Synthetic primer

<400> 34

tctcgccgg cttaagctgc gcatgtgtga gt

32

<210> 35  
<211> 11  
<212> PRT  
<213> Mouse

<400> 35

Ser Gly Phe Asn Ile Lys Asp Thr Tyr Ile His  
1 5 10

<210> 36  
<211> 17  
<212> PRT  
<213> Mouse

<400> 36

Gly Arg Ile Asp Pro 6 Asn Asp Asn Thr Lys Asp Pro Lys Phe Gln  
1 5 10 15

Gly  
17

<210> 37  
<211> 7  
<212> PRT  
<213> Mouse

<400> 37

Pro Pro Phe Tyr Phe Asp Tyr  
1 5

<210> 38  
<211> 11  
<212> PRT  
<213> Mouse

<400> 38

Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala  
1 5 10

<210> 39  
<211> 7  
<212> PRT  
<213> Mouse

<400> 39

Ser Ala Ser Tyr Arg Tyr Ser  
1 5

<210> 40  
<211> 9  
<212> PRT  
<213> Mouse

<400> 40

Gln Gln Tyr Asn Ser Phe Pro Tyr Thr  
1 5

<210> 41  
<211> 116  
<212> PRT  
<213> Mouse

<400> 41

Gln Val Lys Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr  
20 25 30

Tyr Ile His Trp Val Lys Gln Ser Pro Glu Gln Gly Leu Glu Trp Ile  
35 40 45

Gly Trp Ile Asp Pro Pro Asn Asp Asn Thr Lys Tyr Asp Pro Lys Phe  
50 55 60

Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr  
65 70 75 80

Met Gln Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Leu Pro Pro Phe Tyr Phe Asp Tyr Trp Gly His Gly Thr Thr Val  
100 105 110

Thr Val Ser Ser  
115

&lt;210&gt; 42

&lt;211&gt; 109

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 42

Asp Ile Glu Leu Thr Gln Ser Pro Lys Phe Met Ser Thr Ser Val Gly  
1 5 10 15

Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn  
20 25 30

Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile  
35 40 45

Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser  
65 70 75 80

Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Phe Pro Tyr  
85 90 95

Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala  
100 105

&lt;210&gt; 43

&lt;211&gt; 33

&lt;212&gt; DNA

&lt;213&gt; Mouse

&lt;400&gt; 43

tct ggc ttc aac att aaa gac acc tat ata cac  
Ser Gly Phe Asn Ile Lys Asp Thr Tyr Ile His  
1 5 10

33

<210> 44  
<211> 51  
<212> DNA  
<213> Mouse

&lt;400&gt; 44

gga agg atc gat cct ccg aat gat aat act aaa tat gac ccg aag ttc 48  
Gly Arg Ile Asp Pro Pro Asn Asp Asn Thr Lys Asp Pro Lys Phe Gln  
1 5 10 15

cag 51  
Gly  
17

<210> 45  
<211> 21  
<212> DNA  
<213> Mouse

&lt;400&gt; 45

cca ccc ttc tac ttt gac tac 21  
Pro Pro Phe Tyr Phe Asp Tyr  
1 5

<210> 46  
<211> 33  
<212> DNA  
<213> Mouse

&lt;400&gt; 46

aag gcc agt cag aat gtg gat act aat gta gcc 33  
Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala  
1 5 10

<210> 47  
<211> 21  
<212> DNA  
<213> Mouse

&lt;400&gt; 47

tcg gca tcc tac cgg tac agt 21  
Ser Ala Ser Tyr Arg Tyr Ser  
1 5

<210> 48  
<211> 27  
<212> DNA  
<213> Mouse

&lt;400&gt; 48

cag caa tat aac agc ttt cct tac acg 27  
Gln Gln Tyr Asn Ser Phe Pro Tyr Thr  
1 5

<210> 49  
<211> 348  
<212> DNA  
<213> Mouse

&lt;400&gt; 49

cag gtc aaa ctg cag tct ggg gca gag ctt gtc aag c	48
Gln Val Lys Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala	
1 5 10 15	
tca gtc aag ttg tcc tgc aca gct tct ggc ttc aac att aaa gac acc	96
Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr	
20 25 30	
tat ata cac tgg gtg aag cag agc cct gaa cag ggc ctg gag tgg att	144
Tyr Ile His Trp Val Lys Gln Ser Pro Glu Gln Gly Leu Glu Trp Ile	
35 40 45	
gga agg atc gat cct ccg aat gat aat act aaa tat gac ccg aag ttc	192
Gly Trp Ile Asp Pro Pro Asn Asp Asn Thr Lys Tyr Asp Pro Lys Phe	
50 55 60	
cag ggc aag gcc act ata aca gca gac aca tcc tcc aat aca gcc tac	240
Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr	
65 70 75 80	
atg cag ctc cgc agc ctg aca tct gag gac act gcc gtc tat tac tgt	288
Met Gln Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys	
85 90 95	
gcc ctc cca ccg ttc tac ttt gac tac tgg ggc cat ggc acc acg gtc	336
Ala Leu Pro Pro Phe Tyr Phe Asp Tyr Trp Gly His Gly Thr Thr Val	
100 105 110	
acc gtc tcc tca	348
Thr Val Ser Ser	
115	

<210> 50  
 <211> 327  
 <212> DNA  
 <213> Mouse

<400> 50

gac atc gag ctc act cag tct cca aaa ttc atg tcc aca tca gta gga	48
Asp Ile Glu Leu Thr Gln Ser Pro Lys Phe Met Ser Thr Ser Val Gly	
1 5 10 15	
gac agg gtc agc gtc acc tgc aag gcc agt cag aat gtg gat act aat	96
Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn	
20 25 30	
gta gcc tgg tat caa cag aaa cca ggg caa tct cct aaa gca ctg att	144
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile	
35 40 45	
tac tcg gca tcc tac cgg tac agt gga gtc cct gat cgc ttc aca ggc	192
Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly	
50 55 60	
agt gga tct ggg aca gat ttc act ctc acc atc agc aat gtg cag tct	240
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser	
65 70 75 80	
gaa gac ttg gca gag tat ttc tgt cag caa tat aac agc ttt cct tac	288
Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Phe Pro Tyr	
85 90 95	

acg ttc gga ggg ggg ac aag ctg gaa ata aaa cgg gcg  
Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala  
100 105

327

<210> 51  
<211> 240  
<212> PRT  
<213> Mouse

<400> 51

Gln Val Lys Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr  
20 25 30

Tyr Ile His Trp Val Lys Gln Ser Pro Glu Gln Gly Leu Glu Trp Ile  
35 40 45

Gly Trp Ile Asp Pro Pro Asn Asp Asn Thr Lys Tyr Asp Pro Lys Phe  
50 55 60

Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr  
65 70 75 80

Met Gln Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Leu Pro Pro Phe Tyr Phe Asp Tyr Trp Gly His Gly Thr Thr Val  
100 105 110

Thr Val Ser Ser Gly Gly Gly Ser Gly Gly Ser Gly Gly  
115 120 125

Gly Gly Ser Asp Ile Glu Leu Thr Gln Ser Pro Lys Phe Met Ser Thr  
130 135 140

Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val  
145 150 155 160

Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys  
165 170 175

Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg  
180 185 190

Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn  
195 200 205

Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser  
210 215 220

Phe Pro Tyr Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala  
225 230 235 240

<210> 52  
<211> 720  
<212> DNA  
<213> Mouse

<400> 52

cag gtc aaa ctg ca	gag tct ggg gca gag ctt gtc aag	g	ggg gcc	48
Gln Val Lys Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala				
1	5	10	15	
tca gtc aag ttg tcc tgc aca gct tct ggc ttc aac att aaa gac acc				96
Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr				
20	25	30		
tat ata cac tgg gtg aag cag agc cct gaa cag ggc ctg gag tgg att				144
Tyr Ile His Trp Val Lys Gln Ser Pro Glu Gln Gly Leu Glu Trp Ile				
35	40	45		
gga agg atc gat cct ccg aat gat aat act aaa tat gac ccg aag ttc				192
Gly Trp Ile Asp Pro Pro Asn Asp Asn Thr Lys Tyr Asp Pro Lys Phe				
50	55	60		
cag ggc aag gcc act ata aca gca gac aca tcc tcc aat aca gcc tac				240
Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr				
65	70	75	80	
atg cag ctc cgc agc ctg aca tct gag gac act gcc gtc tat tac tgt				288
Met Gln Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys				
85	90	95		
gcc ctc cca ccg ttc tac ttt gac tac tgg ggc cat ggc acc acg gtc				336
Ala Leu Pro Pro Phe Tyr Phe Asp Tyr Trp Gly His Gly Thr Thr Val				
100	105	110		
acc gtc tcc tca ggt gga ggc ggt tca ggc gga ggg ggc tct ggc ggt				384
Thr Val Ser Ser Gly Gly Ser Gly Gly Gly Ser Gly Gly Ser Gly Gly				
115	120	125		
ggc gga tcg gac atc gag ctc act cag tct cca aaa ttc atg tcc aca				432
Gly Gly Ser Asp Ile Glu Leu Thr Gln Ser Pro Lys Phe Met Ser Thr				
130	135	140		
tca gta gga gac agg gtc agc gtc acc tgc aag gcc agt cag aat gtg				480
Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val				
145	150	155	160	
gat act aat gta gcc tgg tat caa cag aaa cca ggg caa tct cct aaa				528
Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys				
165	170	175		
gca ctg att tac tcg gca tcc tac cgg tac agt gga gtc cct gat cgc				576
Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg				
180	185	190		
ttc aca ggc agt gga tct ggg aca gat ttc act ctc acc atc agc aat				624
Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn				
195	200	205		
gtg cag tct gaa gac ttg gca gag tat ttc tgt cag caa tat aac agc				672
Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser				
210	215	220		
ttt cct tac acg ttc gga ggg acc aag ctg gaa ata aaa cgg gcg				720
Phe Pro Tyr Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala				
225	230	235	240	

<210> 53  
 <211> 11  
 <212> PRT  
 <213> Human

&lt;400&gt; 53

Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala  
5 10

&lt;210&gt; 54

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 54

Asp Ser Ser Asn Arg Ala Thr  
5

&lt;210&gt; 55

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 55

Leu Gln His Asn Thr Phe Pro Pro Thr  
5

&lt;210&gt; 56

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 56

Arg Ala Ser Gln Gly Ile Ser Ser Arg Leu Ala  
5 10

&lt;210&gt; 57

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 57

Ala Ala Ser Ser Leu Gln Thr  
5

&lt;210&gt; 58

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 58

Gln Gln Ala Asn Arg Phe Pro Pro Thr  
5

&lt;210&gt; 59

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 59

Ala Gly Thr Thr Asp Leu Thr Tyr Tyr Asp Leu Val Ser  
5 10

<210> 60  
<211> 7  
<212> PRT  
<213> Human

<400> 60

Asp Gly Asn Lys Arg Pro Ser  
5

<210> 61  
<211> 10  
<212> PRT  
<213> Human

<400> 61

Asn Ser Tyr Val Ser Ser Arg Phe Tyr Val  
5 10

<210> 62  
<211> 13  
<212> PRT  
<213> Human

<400> 62

Ser Gly Ser Thr Ser Asn Ile Gly Thr Asn Thr Ala Asn  
5 10

<210> 63  
<211> 7  
<212> PRT  
<213> Human

<400> 63

Asn Asn Asn Gln Arg Pro Ser  
5

<210> 64  
<211> 12  
<212> PRT  
<213> uman

<400> 64

Ala Ala Trp Asp Asp Ser Leu Asn Gly His Trp Val  
5 10

<210> 65  
<211> 10  
<212> PRT  
<213> Human

&lt;400&gt; 65

Gly Phe Thr Phe Ser Ser Tyr Ser Met Asn  
5 10

<210> 66  
<211> 17  
<212> PRT  
<213> Human

&lt;400&gt; 66

Ser Ile Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys  
5 10 15

Gly  
17

<210> 67  
<211> 7  
<212> PRT  
<213> Human

&lt;400&gt; 67

Val Thr Asp Ala Phe Asp Ile  
5

<210> 68  
<211> 10  
<212> PRT  
<213> Human

&lt;400&gt; 68

Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser  
5 10

<210> 69  
<211> 18  
<212> PRT  
<213> Human

&lt;400&gt; 69

Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe  
5 10 15

Gln Gly  
18

<210> 70  
<211> 16  
<212> PRT  
<213> Human

&lt;400&gt; 70

Gly Tyr Asp Tyr Tyr Asp Ser Ser Gly Val Ala Ser Pro Phe Asp Tyr  
5 10 15

<210> 71  
 <211> 375  
 <212> DNA  
 <213> Human

<400> 71

gag gtc cag ctg gtg cag tct ggg gct gag gtg aag aag cct ggg gcc	48
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala	
5 10 15	
tca gtg aag gtc tcc tgc aag gct tct gga ggc acc ttc agc agc tat	96
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr	
20 25 30	
gct atc agc tgg gtg cga cag gcc cct gga caa ggg ctt gag tgg atg	144
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met	
35 40 45	
gga ggg atc atc cct atc ttt ggt aca gca aac tac gca cag aag ttc	192
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe	
50 55 60	
cag ggc aga gtc act ttt acc gcg gac aaa tcc acg agt aca gcc tat	240
Gln Gly Arg Val Thr Phe Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr	
65 70 75 80	
atg gag ttg agg agc ctg aga tct gac gac acg gcc gtg tat tac tgt	288
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys	
85 90 95	
gcg aga gga tac gat tac tat gat agt agt ggc gtg gct tcc ccc ttt	336
Ala Arg Gly Tyr Asp Tyr Tyr Asp Ser Ser Gly Val Ala Ser Pro Phe	
100 105 110	
gac tac tgg ggc cag gga acc ctg gtc acc gtc tca agc	375
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser	
115 120 125	

<210> 72  
 <211> 125  
 <212> PRT  
 <213> Human

<400> 72

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala	
5 10 15	
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr	
20 25 30	
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met	
35 40 45	
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe	
50 55 60	
Gln Gly Arg Val Thr Phe Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr	
65 70 75 80	
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys	
85 90 95	

Ala Arg Gly Tyr Ala Tyr Tyr Asp Ser Ser Gly Val Ala Pro Phe  
 100 105 110

Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
 115 120 125

<210> 73  
 <211> 333  
 <212> DNA  
 <213> Human

<400> 73

cag tct gtg ctg act cag cca ccc tca gcg tct ggg acc ccc ggg cag 48  
 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln  
 5 10 15

agg gtc acc atc tct tgt tct gga agc acc tcc aac atc ggt act aat 96  
 Arg Val Thr Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Thr Asn  
 20 25 30

act gca aac tgg ttc cag cag ctc cca gga acg gcc ccc aaa ctc ctc 144  
 Thr Ala Asn Trp Phe Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45

atc cac aat aat aat cag cgg ccc tca ggg gtc cct gac cga ttc tct 192  
 Ile His Asn Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60

ggc tcc aag tct ggc acc tca gcc tcc ctg gcc atc agt ggg ctc cag 240  
 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln  
 65 70 75 80

tct gag gat gag gct gat tat tac tgt gca gca tgg gat gac agc ctg 288  
 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu  
 85 90 95

aat ggc cat tgg gtg ttc ggc gga ggg acc aag ctg acc gtc ctg 333  
 Asn Gly His Trp Val Phe Gly Gly Thr Lys Leu Thr Val Leu  
 100 105 110

<210> 74  
 <211> 111  
 <212> PRT  
 <213> Human

<400> 74

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln  
 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Thr Asn  
 20 25 30

Thr Ala Asn Trp Phe Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45

Ile His Asn Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln  
 65 70 75 80

Ser Glu Asp Glu Ala **Asp** Tyr Tyr Cys Ala Ala Trp Asp **Asp** Ser Leu  
 85 90 95

Asn Gly His Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu  
 100 105 110

<210> 75  
 <211> 348  
 <212> DNA  
 <213> Human

<400> 75

gag gtg cag ctg gtg cag tct ggg gga ggc ctg gtc aag cct ggg ggg 48  
 Glu Val Gln Leu Val Gln Ser Gly Gly Leu Val Lys Pro Gly Gly  
 5 10 15

tcc ctg aga ctc tcc tgt gca gcc tct gga ttc acc ttc agt agc tat 96  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30

agc atg aac tgg gtc cgc cag gct cca ggg aag ggg ctg gag tgg gtc 144  
 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45

tca tcc att agt agt agt agt tac ata tac tac gca gac tca gtg 192  
 Ser Ser Ile Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val  
 50 55 60

aag ggc cga ttc acc atc tcc aga gac aac gcc aag aac tca ctg tat 240  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr  
 65 70 75 80

ctg caa atg aac agc ctg aga gcc gag gac acg gct gtg tat tac tgt 288  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

gcg aga gtc aca gat gct ttt gat atc tgg ggc caa ggg aca atg gtc 336  
 Ala Arg Val Thr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val  
 100 105 110

acc gtc tca agc 348  
 Thr Val Ser Ser  
 115

<210> 76  
 <211> 116  
 <212> PRT  
 <213> Human

<400> 76

Glu Val Gln Leu Val Gln Ser Gly Gly Leu Val Lys Pro Gly Gly  
 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30

Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45

Ser Ser Ile Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val

50

55

60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr  
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Arg Val Thr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val  
 100 105 110

Thr Val Ser Ser  
 115

&lt;210&gt; 77

&lt;211&gt; 321

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 77

gaa att gtg atg aca cag tct cca gcc acc ctg tct ttg tct cca ggg 48  
 Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly  
 5 10 15

gaa aga gcc acc ctc tcc tgc agg gcc agt cag agt gtt agc agc tac 96  
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr  
 20 25 30

tta gcc tgg tac caa cag aaa cct ggc cag gct ccc agg ctc ctc atc 144  
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile  
 35 40 45

tat gat tca tcc aac agg gcc act ggc atc cca gcc aga ttc agt ggc 192  
 Tyr Asp Ser Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly  
 50 55 60

agt ggg tct ggg aca gac ttc act ctc acc atc agc agc cta gag cct 240  
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro  
 65 70 75 80

gaa gat ttt gca act tat tac tgt cta cag cat aac act ttt cct ccg 288  
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Thr Phe Pro Pro  
 85 90 95

acg ttc ggc caa ggg acc aag gtg gaa atc aaa 321  
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys  
 100 105

&lt;210&gt; 78

&lt;211&gt; 107

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 78

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly  
 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr  
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile

35

40

45

Tyr Asp Ser Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly  
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro  
 65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Thr Phe Pro Pro  
 85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys  
 100 105

<210> 79  
 <211> 348  
 <212> DNA  
 <213> Human

<400> 79

gag gtc cag ctg gtg cag tct ggg gga ggc ctg gtc aag cct ggg ggg 48  
 Glu Val Gln Leu Val Gln Ser Gly Gly Leu Val Lys Pro Gly Gly  
 5 10 15

tcc ctg aga ctc tcc tgt gca gcc tct gga ttc acc ttc agt agc tat 96  
 Ser Leu Arg Ile Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30

agc atg aac tgg gtc cgc cag gct cca ggg aag ggg ctg gag tgg gtc 144  
 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45

tca tcc att agt agt agt agt tac ata tac tac gca gac tca gtg 192  
 Ser Ser Ile Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val  
 50 55 60

aag ggc cga ttc acc atc tcc aga gac aac gcc aag aac tca ctg tat 240  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr  
 65 70 75 80

ctg caa atg aac agc ctg aga gcc gag gac acg gct gtg tat tac tgt 288  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

gcg aga gtc aca gat gct ttt gat atc tgg ggc caa ggg aca atg gtc 336  
 Ala Arg Val Thr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val  
 100 105 110

acc gtc tca agc 348  
 Thr Val Ser Ser  
 115

<210> 80  
 <211> 330  
 <212> DNA  
 <213> Human

<400> 80

cag tct gcc ctg act cag cct gcc tcc ctg tct ggg tct cct gga cag 48  
 Gln Ser Ala Leu Thr Gln Pro Ala Ser Leu Ser Gly Ser Pro Gly Gln  
 5 10 15

tcg atc acc atc tcg gct gga acc acc act gat ctt	8	tat tat	96
Ser Ile Thr Ile Ser Cys Ala Gly Thr Thr Thr Asp Leu Thr Tyr Tyr			
20	25	30	
gac ctt gtc tcc tgg tac caa cag cac cca ggc caa gca ccc aaa ctc			144
Asp Leu Val Ser Trp Tyr Gln Gln His Pro Gly Gln Ala Pro Lys Leu			
35	40	45	
gtg att tat gac ggc aat aag cgg ccc tca gga gtt tct aat cgc ttc			192
Val Ile Tyr Asp Gly Asn Lys Arg Pro Ser Gly Val Ser Asn Arg Phe			
50	55	60	
tct ggc tcc aag tct ggc aac acg gcc tcc ctg aca atc tct gga ctc			240
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu			
65	70	75	80
cag gct gag gac gag gct gat tat tac tgc aac tca tat gta agc agc			288
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Val Ser Ser			
85	90	95	
agg ttt tat gtc ttc gga act ggg acc aag gtc acc gtc cta			330
Arg Phe Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu			
100	105	110	

<210> 81  
<211> 110  
<212> PRT  
<213> Human

<400> 81

Gln Ser Ala Leu Thr Gln Pro Ala Ser Leu Ser Gly Ser Pro Gly Gln  
5 10 15

Ser Ile Thr Ile Ser Cys Ala Gly Thr Thr Thr Asp Leu Thr Tyr Tyr  
20 25 30

Asp Leu Val Ser Trp Tyr Gln Gln His Pro Gly Gln Ala Pro Lys Leu  
35 40 45

Val Ile Tyr Asp Gly Asn Lys Arg Pro Ser Gly Val Ser Asn Arg Phe  
50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu  
65 70 75 80

Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Val Ser Ser  
85 90 95

Arg Phe Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu  
100 105 110

<210> 82  
<211> 348  
<212> DNA  
<213> Human

<400> 82

gaa gtg cag ctg gtg cag tct ggg gga ggc ctg gtc aag cct ggg ggg  
Glu Val Gln Leu Val Gln Ser Gly Gly Leu Val Lys Pro Gly Gly  
5 10 15

tcc	ctg	aga	ctc	tc	gt	gca	gcc	tct	gga	ttc	acc	ttc	agc	tat	96
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
20													30		
25															
35													45		
40															
50													60		
55															
65													80		
70															
75															
85													95		
90															
100													110		
105															
110															
115															

<210> 83  
<211> 116  
<212> PRT  
<213> Human

<400> 83

Glu	Val	Gln	Leu	Val	Gln	Ser	Gly	Gly	Leu	Val	Lys	Pro	Gly	Gly	
5													15		
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
20													30		
Ser	Met	Asn	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
35													45		
Ser	Ser	Ile	Ser	Ser	Ser	Ser	Tyr	Ile	Tyr	Tyr	Ala	Asp	Ser	Val	
50													60		
Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asp	Ser	Leu	Tyr
65													80		
Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
85													95		
Ala	Arg	Val	Thr	Asp	Ala	Phe	Asp	Ile	Trp	Gly	Gln	Gly	Thr	Met	Val
100													110		
Thr	Val	Ser	Ser												
115															

<210> 84  
<211> 321  
<212> DNA  
<213> Human

&lt;400&gt; 84

gac atc cag ttg acc cag tct cca tct tct gtg tct gca tct gta gga	48
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly	
5 10 15	
gac aga gtc acc atc act tgt cgg gcg agt cag ggt att agt agt cgg	96
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Arg	
20 25 30	
tta gcc tgg tat cag cag aaa cca ggg aaa gcc cct aag ctc ctg atc	144
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Ile Ile	
35 40 45	
tat gct gca tcc agt ttg caa act ggg gtc cca tca agg ttc agc ggc	192
Tyr Ala Ala Ser Ser Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly	
50 55 60	
agt gga tct ggg aca gat ttc act ctc act atc agc agc ctg cag cct	240
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro	
65 70 75 80	
gaa gat ttt gca act tac tat tgt caa cag gct aac agg ttc cct ccg	288
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Arg Phe Pro Pro	
85 90 95	
act ttc ggc cct ggg acc aaa gtg gat atc aaa	321
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys	
100 105	

<210> 85  
 <211> 107  
 <212> PRT  
 <213> Human

&lt;400&gt; 85

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly	
5 10 15	
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Arg	
20 25 30	
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Ile Ile	
35 40 45	
Tyr Ala Ala Ser Ser Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly	
50 55 60	
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro	
65 70 75 80	
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Arg Phe Pro Pro	
85 90 95	
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys	
100 105	

<210> 86  
 <211> 333  
 <212> DNA  
 <213> Human

&lt;400&gt; 86

cag tct gtc gtg acg cag ccg ccc tca gtg tct ggg gcc cca ggg cag	48
Gln Ser Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln	
5 10 15	
agg gtc acc atc tcc tgc act ggg agc cac tcc aac ttc ggg gca gga	96
Arg Val Thr Ile Ser Cys Thr Gly Ser His Ser Asn Phe Gly Ala Gly	
20 25 30	
act gat gta cat tgg tac caa cac ctt cca gga aca gcc ccc aga ctc	144
Thr Asp Val His Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Arg Leu	
35 40 45	
ctc att cat gga gac agt aat cgg ccc tcc ggg gtc cct gac cga ttc	192
Leu Ile His Gly Asp Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe	
50 55 60	
tct ggc tcc agg tct ggc acc tca gcc tcc ctg gcc atc act ggg ctc	240
Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu	
65 70 75 80	
cgg gtt gag gat gag gct gat tat tac tgt cag tcg tat gac tat ggc	288
Arg Val Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Tyr Gly	
85 90 95	
ctg aga ggt tgg gtg ttc ggc ggc ggg acc aag ctg acc gtc ctt	333
Leu Arg Gly Trp Val Phe Gly Gly Thr Lys Leu Thr Val Leu	
100 105 110	

<210> 87  
 <211> 111  
 <212> PRT  
 <213> Human

&lt;400&gt; 87

Gln Ser Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln	
5 10 15	
Arg Val Thr Ile Ser Cys Thr Gly Ser His Ser Asn Phe Gly Ala Gly	
20 25 30	
Thr Asp Val His Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Arg Leu	
35 40 45	
Leu Ile His Gly Asp Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe	
50 55 60	
Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu	
65 70 75 80	
Arg Val Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Tyr Gly	
85 90 95	
Leu Arg Gly Trp Val Phe Gly Gly Thr Lys Leu Thr Val Leu	
100 105 110	

<210> 88  
 <211> 321  
 <212> DNA  
 <213> Human

&lt;400&gt; 88

gat gtt gtg atg act cag tct cca tcg tcc ctg tct gca tct gta ggg	48
Asp Val Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly	
5 10 15	
gac aga gtc acc atc act tgc cgg gca agt cag aac att aac aac tat	96
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asn Ile Asn Asn Tyr	
20 25 30	
tta aat tgg tat caa cag aaa cca gga aaa gcc cct aag ctc ctg atc	144
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile	
35 40 45	
tat gct gcc tcc act ttg caa agt ggg gtc cca tca agg ttc agt ggc	192
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly	
50 55 60	
agt gga tct ggg aca gat ttc act ctc acc atc acc agc cta cag cct	240
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Leu Gln Pro	
65 70 75 80	
gaa gat tct gca act tat tac tgc caa cag tat tcc cgt tat cct ccc	288
Glu Asp Ser Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Arg Tyr Pro Pro	
85 90 95	
act ttc ggc gga ggg acc aag gtg gag atc aca	321
Thr Phe Gly Gly Thr Lys Val Glu Ile Thr	
100 105	

<210> 89  
 <211> 107  
 <212> PRT  
 <213> Human

&lt;400&gt; 89

Asp Val Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly	
5 10 15	
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asn Ile Asn Asn Tyr	
20 25 30	
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile	
35 40 45	
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly	
50 55 60	
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Leu Gln Pro	
65 70 75 80	
Glu Asp Ser Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Arg Tyr Pro Pro	
85 90 95	
Thr Phe Gly Gly Thr Lys Val Glu Ile Thr	
100 105	

<210> 90  
 <211> 330  
 <212> DNA  
 <213> Human

&lt;400&gt; 90

cag tct gcc ctg act cag cct gcc tcc gtg tct ggg tct cgt gga cag	48
Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Arg Gly Gln	
5 10 15	
tcg atc acc ctc tcc tgc acc ggc tcc agc act gat gtg ggt aat tat	96
Ser Ile Thr Leu Ser Cys Thr Gly Ser Ser Thr Asp Val Gly Asn Tyr	
20 25 30	
aac tat atc tcc tgg tac caa caa cac cca ggc caa gcc ccc aaa ctc	144
Asn Tyr Ile Ser Trp Tyr Gln Gln His Pro Gly Gln Ala Pro Lys Leu	
35 40 45	
ttg att tac gat gtc act agt cgg ccc tca ggt gtt tct gat cgc ttc	192
Leu Ile Tyr Asp Val Thr Ser Arg Pro Ser Gly Val Ser Asp Arg Phe	
50 55 60	
tct ggc tcc aag tca ggc ctc acg gcc tcc ctg acc atc tct gga ctc	240
Ser Gly Ser Lys Ser Gly Leu Thr Ala Ser Leu Thr Ile Ser Gly Leu	
65 70 75 80	
cag cct gaa gac gag gct gac tat tac tgc aac tcc tat tct gcc acc	288
Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Ser Ala Thr	
85 90 95	
gac act ctt gtt ttt ggc gga ggg acc aag ctg acc gtc cta	330
Asp Thr Leu Val Phe Gly Gly Thr Lys Leu Thr Val Leu	
100 105 110	

<210> 91  
 <211> 110  
 <212> PRT  
 <213> Human

&lt;400&gt; 91

Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Arg Gly Gln	
5 10 15	
Ser Ile Thr Leu Ser Cys Thr Gly Ser Ser Thr Asp Val Gly Asn Tyr	
20 25 30	
Asn Tyr Ile Ser Trp Tyr Gln Gln His Pro Gly Gln Ala Pro Lys Leu	
35 40 45	
Leu Ile Tyr Asp Val Thr Ser Arg Pro Ser Gly Val Ser Asp Arg Phe	
50 55 60	
Ser Gly Ser Lys Ser Gly Leu Thr Ala Ser Leu Thr Ile Ser Gly Leu	
65 70 75 80	
Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Ser Ala Thr	
85 90 95	
Asp Thr Leu Val Phe Gly Gly Thr Lys Leu Thr Val Leu	
100 105 110	

<210> 92  
 <211> 333  
 <212> DNA  
 <213> Human

&lt;400&gt; 92

cag	gct	gtg	ctg	act	cag	ccg	tcc	tca	gtg	tct	ggg	gcc	cca	gga	cag	48
Gln	Ala	Val	Leu	Thr	Gln	Pro	Ser	Ser	Val	Ser	Gly	Ala	Pro	Gly	Gln	
5									10						15	
agg	gtc	acc	atc	tcc	tgc	act	ggg	caa	agc	tcc	aat	atc	ggg	gca	gat	96
Arg	Val	Thr	Ile	Ser	Cys	Thr	Gly	Gln	Ser	Ser	Asn	Ile	Gly	Ala	Asp	
20									25						30	
tat	gat	gta	cat	tgg	tac	cag	caa	ttt	cca	gga	aca	gcc	ccc	aaa	ctc	144
Tyr	Asp	Val	His	Trp	Tyr	Gln	Gln	Phe	Pro	Gly	Thr	Ala	Pro	Lys	Leu	
35								40						45		
ctc	atc	tat	ggt	cac	aac	aat	cgg	ccc	tca	ggg	gtc	cct	gac	cga	ttc	192
Leu	Ile	Tyr	Gly	His	Asn	Asn	Arg	Pro	Ser	Gly	Val	Pro	Asp	Arg	Phe	
50								55						60		
tct	ggc	tcc	aag	tct	ggc	acc	tca	gtc	tcc	ctg	gtc	atc	agt	ggg	ctc	240
Ser	Gly	Ser	Lys	Ser	Gly	Thr	Ser	Val	Ser	Leu	Val	Ile	Ser	Gly	Leu	
65								70						80		
cag	gct	gag	gat	gag	gct	gat	tat	tat	tgc	cag	tcc	tat	gac	agc	agt	288
Gln	Ala	Glu	Asp	Glu	Ala	Asp	Tyr	Tyr	Cys	Gln	Ser	Tyr	Asp	Ser	Ser	
85								90						95		
cta	agt	ggt	ttg	gta	tcc	ggc	gga	ggg	acc	aag	gtg	acc	gtc	cta	333	
Leu	Ser	Gly	Leu	Val	Phe	Gly	Gly	Thr	Lys	Val	Thr	Val	Thr	Leu		
100								105						110		

<210> 93  
 <211> 111  
 <212> PRT  
 <213> Human

&lt;400&gt; 93

Gln	Ala	Val	Leu	Thr	Gln	Pro	Ser	Ser	Val	Ser	Gly	Ala	Pro	Gly	Gln
5									10						15
Arg	Val	Thr	Ile	Ser	Cys	Thr	Gly	Gln	Ser	Ser	Asn	Ile	Gly	Ala	Asp
20									25						30
Tyr	Asp	Val	His	Trp	Tyr	Gln	Gln	Phe	Pro	Gly	Thr	Ala	Pro	Lys	Leu
35								40						45	
Leu	Ile	Tyr	Gly	His	Asn	Asn	Arg	Pro	Ser	Gly	Val	Pro	Asp	Arg	Phe
50								55						60	
Ser	Gly	Ser	Lys	Ser	Gly	Thr	Ser	Val	Ser	Leu	Val	Ile	Ser	Gly	Leu
65								70						80	
Gln	Ala	Glu	Asp	Glu	Ala	Asp	Tyr	Tyr	Cys	Gln	Ser	Tyr	Asp	Ser	Ser
85								90						95	
Leu	Ser	Gly	Leu	Val	Phe	Gly	Gly	Thr	Lys	Val	Thr	Val	Leu		
100								105						110	

<210> 94  
 <211> 321  
 <212> DNA  
 <213> Human

&lt;400&gt; 94

gac atc cag ttg acc cag tct cca tct tct gtg tct gca tct gtt gga	48
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly	
5 10 15	
gac agc gtc acc atc act tgt cgg gcg agt cag gat att agc agc tgg	96
Asp Ser Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Ser Trp	
20 25 30	
tta gcc tgg tat caa cag aaa cca ggg gag gcc cct aag ctc ctg atc	144
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Glu Ala Pro Lys Leu Leu Ile	
35 40 45	
tat gct gca tcc ctt ctt caa agt ggg gtc cca tca cgg ttc agc ggc	192
Tyr Ala Ala Ser Leu Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly	
50 55 60	
agt gga tct ggg aca gat ttc gct ctc act atc aac agc ctg cag cct	240
Ser Gly Ser Gly Thr Asp Phe Ala Leu Thr Ile Asn Ser Leu Gln Pro	
65 70 75 80	
gaa gat ttt gca act tac ttt tgt caa cag gct gac agt ttc cct ccc	288
Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Ala Asp Ser Phe Pro Pro	
85 90 95	
acc ttc ggc caa ggg aca cgg ctg gag att aaa	321
Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys	
100 105	

<210> 95  
 <211> 107  
 <212> PRT  
 <213> Human

&lt;400&gt; 95

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly	
5 10 15	
Asp Ser Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Ser Trp	
20 25 30	
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Glu Ala Pro Lys Leu Leu Ile	
35 40 45	
Tyr Ala Ala Ser Leu Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly	
50 55 60	
Ser Gly Ser Gly Thr Asp Phe Ala Leu Thr Ile Asn Ser Leu Gln Pro	
65 70 75 80	
Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Ala Asp Ser Phe Pro Pro	
85 90 95	
Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys	
100 105	

<210> 96  
 <211> 321  
 <212> DNA  
 <213> Human

&lt;400&gt; 96

gac atc gag ttg acc cag tct cca tct tcc gtg tct gca tct gtg gga	48
Asp Ile Glu Leu Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly	
5 10 15	
gac aga gtc acc ctc act tgt cgg gcg agt cag agt att aag agg agg tgg	96
Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Ser Ile Lys Arg Trp	
20 25 30	
tta gcc tgg tat cag cag aaa cca ggg aag gcc cct agg ctc ctc atc	144
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile	
35 40 45	
tat gct gca tcc act ttg caa agt ggg gtc cca tca agg ttc agc ggc	192
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly	
50 55 60	
ggt gga tct ggg aca gat ttc act ctc acc atc aac agc ctg cag cct	240
Gly Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro	
65 70 75 80	
gaa gat ttt gca att tac tac tgt caa cag gct aac agt ttc cct ccc	288
Glu Asp Phe Ala Ile Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Pro	
85 90 95	
act ttc ggc cct ggg acc aaa gtg gat atc aaa	321
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys	
100 105	

<210> 97  
 <211> 107  
 <212> PRT  
 <213> Human

&lt;400&gt; 97

Asp Ile Glu Leu Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly	
5 10 15	
Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Ser Ile Lys Arg Trp	
20 25 30	
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile	
35 40 45	
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly	
50 55 60	
Gly Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro	
65 70 75 80	
Glu Asp Phe Ala Ile Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Pro	
85 90 95	
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys	
100 105	

<210> 98  
 <211> 333  
 <212> DNA  
 <213> Human

&lt;400&gt; 98

cag tct gtc gtg acg cag ccg ccc tca gtg tct ggg gcc cca ggg cag	48
Gln Ser Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln	
5 10 15	
agg gtc acc atc tcc tgc agt ggg agc agg tcc aac atc ggg gca cac	96
Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly Ala His	
20 25 30	
tat gaa gtc cag tgg tac cag cag ttt ccg gga gca gcc ccc aaa ctc	144
Tyr Glu Val Gln Trp Tyr Gln Gln Phe Pro Gly Ala Ala Pro Lys Leu	
35 40 45	
ctc atc tat ggt gac acc aat cgg ccc tca ggg gtc cct gac cga ttc	192
Leu Ile Tyr Gly Asp Thr Asn Arg Pro Ser Gly Val Pro Asp Arg Phe	
50 55 60	
tct gcc tcc cac tct ggc acc tca gcc tcc ctt gcc atc aca ggg ctc	240
Ser Ala Ser His Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu	
65 70 75 80	
cag gct gag gat gag gct gat tat tac tgc cag tcg tat gac acc agt	288
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser	
85 90 95	
cta cgt ggt ccg gtg ttc ggc gga ggg acc aag ctg acc gtc cta	333
Leu Arg Gly Pro Val Phe Gly Gly Thr Lys Leu Thr Val Leu	
100 105 110	

<210> 99  
 <211> 111  
 <212> PRT  
 <213> Human

&lt;400&gt; 99

Gln Ser Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln	
5 10 15	
Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly Ala His	
20 25 30	
Tyr Glu Val Gln Trp Tyr Gln Gln Phe Pro Gly Ala Ala Pro Lys Leu	
35 40 45	
Leu Ile Tyr Gly Asp Thr Asn Arg Pro Ser Gly Val Pro Asp Arg Phe	
50 55 60	
Ser Ala Ser His Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu	
65 70 75 80	
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser	
85 90 95	
Leu Arg Gly Pro Val Phe Gly Gly Thr Lys Leu Thr Val Leu	
100 105 110	

<210> 100  
 <211> 333  
 <212> DNA  
 <213> Human

&lt;400&gt; 100

cag tct gtc gtg acg cag ccg ccc tca gtg tct ggg gcc cca ggg cag	48
Gln Ser Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln	
5 10 15	
agg gtc acc atc tcc tgc act ggg agc agc tcc aac atc ggg aca ggt	96
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Asn Ile Gly Thr Gly	
20 25 30	
tat gat gta cat tgg tac cag cag gtt cca gga tca gcc ccc aaa ctc	144
Tyr Asp Val His Trp Tyr Gln Gln Val Pro Gly Ser Ala Pro Lys Leu	
35 40 45	
ctc atc tat gct tac acc aat cgg ccc tca ggg gtc cct gac cga ttc	192
Leu Ile Tyr Ala Tyr Thr Asn Arg Pro Ser Gly Val Pro Asp Arg Phe	
50 55 60	
tct ggc tcc aag tct ggc atg tca gcc tcc ctg gtc atc ggt ggt ctc	240
Ser Gly Ser Lys Ser Gly Met Ser Ala Ser Leu Val Ile Gly Gly Leu	
65 70 75 80	
cag gct gag gat gag gct gat tat tac tgc cag tcc ttt gac gac agc	288
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Phe Asp Asp Ser	
85 90 95	
ctg aat ggt ctt gtc ttc gga cct ggg acc tcg gtc acc gtc ctc	333
Leu Asn Gly Leu Val Phe Gly Pro Gly Thr Ser Val Thr Val Leu	
100 105 110	

<210> 101  
 <211> 111  
 <212> PRT  
 <213> Human

&lt;400&gt; 101

Gln Ser Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln	
5 10 15	
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Thr Gly	
20 25 30	
Tyr Asp Val His Trp Tyr Gln Gln Val Pro Gly Ser Ala Pro Lys Leu	
35 40 45	
Leu Ile Tyr Ala Tyr Thr Asn Arg Pro Ser Gly Val Pro Asp Arg Phe	
50 55 60	
Ser Gly Ser Lys Ser Gly Met Ser Ala Ser Leu Val Ile Gly Gly Leu	
65 70 75 80	
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Phe Asp Asp Ser	
85 90 95	
Leu Asn Gly Leu Val Phe Gly Pro Gly Thr Ser Val Thr Val Leu	
100 105 110	

<210> 102  
 <211> 333  
 <212> DNA  
 <213> Human

&lt;400&gt; 102

cag tct gtg ttg acg cag ccg ccc tca gtg tct ggg gcc cca ggg cag	48
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln	
5 10 15	
agg gtc acc atc tcc tgc act ggg agc cac tcc aac ttc ggg gca ggt	96
Arg Val Thr Ile Ser Cys Thr Gly Ser His Ser Asn Phe Gly Ala Gly	
20 25 30	
act gat gtc cat tgg tac caa cac ctt cca gga aca gcc ccc aga ctc	144
Thr Asp Val His Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Arg Leu	
35 40 45	
ctc att cat gga gac act cat cgg ccc tcc ggg gtc gct gac cga ttc	192
Leu Ile His Gly Asp Thr His Arg Pro Ser Gly Val Ala Asp Arg Phe	
50 55 60	
tct ggc tcc agg tct ggc gcc tca gcc tcc ctg gcc atc act ggg ctc	240
Ser Gly Ser Arg Ser Gly Ala Ser Ala Ser Leu Ala Ile Thr Gly Leu	
65 70 75 80	
cgg gtt gag gat gag gct gat tat tac tgt cag tcg tat gac tat ggc	288
Arg Val Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Tyr Gly	
85 90 95	
ctg aga ggt tgg gtg ttc ggc ggc ggg acc aag ctg acc gtc ctt	333
Leu Arg Gly Trp Val Phe Gly Gly Thr Lys Leu Thr Val Leu	
100 105 110	

<210> 103  
 <211> 111  
 <212> PRT  
 <213> Human

&lt;400&gt; 103

Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln	
5 10 15	
Arg Val Thr Ile Ser Cys Thr Gly Ser His Ser Asn Phe Gly Ala Gly	
20 25 30	
Thr Asp Val His Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Arg Leu	
35 40 45	
Leu Ile His Gly Asp Thr His Arg Pro Ser Gly Val Ala Asp Arg Phe	
50 55 60	
Ser Gly Ser Arg Ser Gly Ala Ser Ala Ser Leu Ala Ile Thr Gly Leu	
65 70 75 80	
Arg Val Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Tyr Gly	
85 90 95	
Leu Arg Gly Trp Val Phe Gly Gly Thr Lys Leu Thr Val Leu	
100 105 110	

<210> 104  
 <211> 321  
 <212> DNA  
 <213> Human

&lt;400&gt; 104

gac atc cag atg acc cag tct cca tct tcc gtg tct gca tct ata gga	48
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Ile Gly	
5 10 15	
gac aga gtc acc atc act tgt cgg gcg agt cag ggt att gac aac tgg	96
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asp Asn Trp	
20 25 30	
tta ggc tgg tat cag cag aaa cct ggg aaa gcc cct aaa ctc ctg atc	144
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile	
35 40 45	
tac gat gca tcc aat ttg gac aca ggg gtc cca tca agg ttc agt gga	192
Tyr Asp Ala Ser Asn Leu Asp Thr Gly Val Pro Ser Arg Phe Ser Gly	
50 55 60	
agt gga tct ggg aca tat ttt act ctc acc atc agt agc ctg caa gct	240
Ser Gly Ser Gly Thr Tyr Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala	
65 70 75 80	
gaa gat ttt gca gtt tat ttc tgt caa cag gct aaa gct ttt cct ccc	288
Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Ala Lys Ala Phe Pro Pro	
85 90 95	
act ttc ggc gga ggg acc aag gtg gac atc aaa	321
Thr Phe Gly Gly Thr Lys Val Asp Ile Lys	
100 105	

<210> 105  
 <211> 107  
 <212> PRT  
 <213> Human

&lt;400&gt; 105

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Ile Gly	
5 10 15	
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asp Asn Trp	
20 25 30	
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile	
35 40 45	
Tyr Asp Ala Ser Asn Leu Asp Thr Gly Val Pro Ser Arg Phe Ser Gly	
50 55 60	
Ser Gly Ser Gly Thr Tyr Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala	
65 70 75 80	
Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Ala Lys Ala Phe Pro Pro	
85 90 95	
Thr Phe Gly Gly Thr Lys Val Asp Ile Lys	
100 105	

<210> 106  
 <211> 13  
 <212> PRT  
 <213> Human

&lt;400&gt; 106

Thr Gly Ser His Ser Asn Phe Gly Ala Gly Thr Asp Val  
5 10

<210> 107  
<211> 7  
<212> PRT  
<213> Human

&lt;400&gt; 107

Gly Asp Ser Asn Arg Pro Ser  
5

<210> 108  
<211> 11  
<212> PRT  
<213> Human

&lt;400&gt; 108

Gln Ser Tyr Asp Tyr Gly Leu Arg Gly Trp Val  
5 10

<210> 109  
<211> 11  
<212> PRT  
<213> Human

&lt;400&gt; 109

Arg Ala Ser Gln Asn Ile Asn Asn Tyr Leu Asn  
5 10

<210> 110  
<211> 7  
<212> PRT  
<213> Human

&lt;400&gt; 110

Ala Ala Ser Thr Leu Gln Ser  
5

<210> 111  
<211> 9  
<212> PRT  
<213> Human

&lt;400&gt; 111

Gln Gln Tyr Ser Arg Tyr Pro Pro Thr  
5

<210> 112  
<211> 14  
<212> PRT  
<213> Human

&lt;400&gt; 112

Thr Gly Ser Ser Thr Asp Val Gly Asn Tyr Asn Tyr Ile Ser  
5 10

<210> 113  
<211> 7  
<212> PRT  
<213> Human

&lt;400&gt; 113

Asp Val Thr Ser Arg Pro Ser  
5

<210> 114  
<211> 10  
<212> PRT  
<213> Human

&lt;400&gt; 114

Asn Ser Tyr Ser Ala Thr Asp Thr Leu Val  
5 10

<210> 115  
<211> 14  
<212> PRT  
<213> Human

&lt;400&gt; 115

Thr Gly Gln Ser Ser Asn Ile Gly Ala Asp Tyr Asp Val His  
5 10

<210> 116  
<211> 7  
<212> PRT  
<213> Human

&lt;400&gt; 116

Gly His Asn Asn Arg Pro Ser  
5

<210> 117  
<211> 11  
<212> PRT  
<213> Human

&lt;400&gt; 117

Gln Ser Tyr Asp Ser Ser Leu Ser Gly Leu Val  
5 10

<210> 118  
<211> 11  
<212> PRT  
<213> Human

&lt;400&gt; 118

Arg Ala Ser Gln Asp Ile Ser Ser Trp Leu Ala  
5 10

<210> 119  
<211> 7  
<212> PRT  
<213> Human

&lt;400&gt; 119

Ala Ala Ser Leu Leu Gln Ser  
5

<210> 120  
<211> 9  
<212> PRT  
<213> Human

&lt;400&gt; 120

Gln Gln Ala Asp Ser Phe Pro Pro Thr  
5

<210> 121  
<211> 11  
<212> PRT  
<213> Human

&lt;400&gt; 121

Arg Ala Ser Gln Ser Ile Lys Arg Trp Leu Ala  
5 10

<210> 122  
<211> 7  
<212> PRT  
<213> Human

&lt;400&gt; 122

Ala Ala Ser Thr Leu Gln Ser  
5

<210> 123  
<211> 9  
<212> PRT  
<213> Human

&lt;400&gt; 123

Gln Gln Ala Asn Ser Phe Pro Pro Thr  
5

<210> 124  
<211> 14  
<212> PRT  
<213> Human

&lt;400&gt; 124

Ser Gly Ser Arg Ser Asn Ile Gly Ala His Tyr Glu Val Gln  
5 10

<210> 125  
<211> 7  
<212> PRT  
<213> Human

&lt;400&gt; 125

Gly Asp Thr Asn Arg Pro Ser  
5

<210> 126  
<211> 11  
<212> PRT  
<213> Human

&lt;400&gt; 126

Gln Ser Tyr Asp Thr Ser Leu Arg Gly Pro Val  
5 10

<210> 127  
<211> 14  
<212> PRT  
<213> Human

&lt;400&gt; 127

Thr Gly Ser Ser Asn Ile Gly Thr Gly Tyr Asp Val His  
5 10

<210> 128  
<211> 7  
<212> PRT  
<213> Human

&lt;400&gt; 128

Ala Tyr Thr Asn Arg Pro Ser  
5

<210> 129  
<211> 11  
<212> PRT  
<213> Human

&lt;400&gt; 129

Gln Ser Phe Asp Asp Ser Leu Asn Gly Leu Val  
5 10

<210> 130  
<211> 14  
<212> PRT  
<213> Human

&lt;400&gt; 130

Thr Gly Ser His Ser Asn Phe Gly Ala Gly Thr Asp Val His  
5 10

<210> 131  
<211> 7  
<212> PRT  
<213> Human

&lt;400&gt; 131

Gly Asp Thr His Arg Pro Ser  
5

<210> 132  
<211> 11  
<212> PRT  
<213> Human

&lt;400&gt; 132

Gln Ser Tyr Asp Tyr Gly Leu Arg Gly Trp Val  
5 10

<210> 133  
<211> 11  
<212> PRT  
<213> Human

&lt;400&gt; 133

Arg Ala Ser Gln Gly Ile Asp Asn Trp Leu Gly  
5 10

<210> 134  
<211> 7  
<212> PRT  
<213> Human

&lt;400&gt; 134

Asp Ala Ser Asn Leu Asp Thr  
5

<210> 135  
<211> 9  
<212> PRT  
<213> Human

&lt;400&gt; 135

Gln Gln Ala Lys Ala Phe Pro Pro Thr  
5

<210> 136  
<211> 2351  
<212> DNA  
<213> Human

&lt;400&gt; 136

ggtaccgag aaagaaccgg ctcccgagtt ctggcattt cgcccggtc gaggtgcagg	59
atg cag agc aag gtg ctg ctg gcc gtc gcc ctg tgg ctc tgc gtg gag	107
Met Gln Ser Lys Val Leu Leu Ala Val Ala Leu Trp Leu Cys Val Glu	
5 10 15	
acc cgg gcc gcc tct gtg ggt ttg cct agt gtt tct ctt gat ctg ccc	155
Thr Arg Ala Ala Ser Val Gly Leu Pro Ser Val Ser Leu Asp Leu Pro	
20 25 30	
agg ctc agc ata caa aaa gac ata ctt aca att aag gct aat aca act	203
Arg Leu Ser Ile Gln Lys Asp Ile Leu Thr Ile Lys Ala Asn Thr Thr	
35 40 45	
ctt caa att act tgc agg gga cag agg gac ttg gac tgg ctt tgg ccc	251
Leu Gln Ile Thr Cys Arg Gly Gln Arg Asp Leu Asp Trp Leu Trp Pro	
50 55 60	
aat aat cag agt ggc agt gag caa agg gtg gag gtg act gag tgc agc	299
Asn Asn Gln Ser Gly Ser Glu Gln Arg Val Glu Val Thr Glu Cys Ser	
65 70 75 80	
gat ggc ctc ttc tgt aag aca ctc aca att cca aaa gtg atc gga aat	347
Asp Gly Leu Phe Cys Lys Thr Leu Thr Ile Pro Lys Val Ile Gly Asn	
85 90 95	
gac act gga gcc tac aag tgc ttc tac cgg gaa act gac ttg gcc tcg	395
Asp Thr Gly Ala Tyr Lys Cys Phe Tyr Arg Glu Thr Asp Leu Ala Ser	
100 105 110	
gtc att tat gtc tat gtt caa gat tac aga tct cca ttt att gct tct	443
Val Ile Tyr Val Tyr Val Gln Asp Tyr Arg Ser Pro Phe Ile Ala Ser	
115 120 125	
gtt agt gac caa cat gga gtc gtg tac att act gag aac aaa aac aaa	491
Val Ser Asp Gln His Gly Val Val Tyr Ile Thr Glu Asn Lys Asn Lys	
130 135 140	
act gtg gtg att cca tgt ctc ggg tcc att tca aat ctc aac gtg tca	539
Thr Val Val Ile Pro Cys Leu Gly Ser Ile Ser Asn Leu Asn Val Ser	
145 150 155 160	
ctt tgt gca aga tac cca gaa aag aga ttt gtt cct gat ggt aac aga	587
Leu Cys Ala Arg Tyr Pro Glu Lys Arg Phe Val Pro Asp Gly Asn Arg	
165 170 175	
att tcc tgg gac agc aag aag ggc ttt act att ccc agc tac atg atc	635
Ile Ser Trp Asp Ser Lys Lys Gly Phe Thr Ile Pro Ser Tyr Met Ile	
180 185 190	
agc tat gct ggc atg gtc ttc tgt gaa gca aaa att aat gat gaa agt	683
Ser Tyr Ala Gly Met Val Phe Cys Glu Ala Lys Ile Asn Asp Glu Ser	
195 200 205	
tac cag tct att atg tac ata gtt gtc gtt gta ggg tat agg att tat	731
Tyr Gln Ser Ile Met Tyr Ile Val Val Val Gly Tyr Arg Ile Tyr	
210 215 220	
gat gtg gtt ctg agt ccg tct cat gga att gaa cta tct gtt gga gaa	779
Asp Val Val Leu Ser Pro Ser His Gly Ile Glu Leu Ser Val Gly Glu	
225 230 235 240	
aag ctt gtc tta aat tgt aca gca aga act gaa cta aat gtg ggg att	827

Lys	Leu	Val	Leu	Asn	lys	Thr	Ala	Arg	Thr	Glu	Leu	Asn	Gly	Ile
245						250							255	

gac ttc aac tgg gaa tac cct tct tcg aag cat cag cat aag aaa ctt 875  
Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys His Gln His Lys Lys Leu  
260 265 270

gta aac cga gac cta aaa acc cag tct ggg agt gag atg aag aaa ttt 923  
Val Asn Arg Asp Leu Lys Thr Gln Ser Gly Ser Glu Met Lys Lys Phe  
275 280 285

ttg agc acc tta act ata gat ggt gta acc cgg agt gac caa gga ttg 971  
Leu Ser Thr Leu Thr Ile Asp Gly Val Thr Arg Ser Asp Gln Gly Leu  
290 295 300

tac acc tgt gca gca tcc agt ggg ctg atg acc aag aag aac agc aca 1019  
Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met Thr Lys Lys Asn Ser Thr  
305 310 315 320

ttt gtc agg gtc cat gaa aaa cct ttt gtt gct ttt gga agt ggc atg 1067  
Phe Val Arg Val His Glu Lys Pro Phe Val Ala Phe Gly Ser Gly Met  
325 330 335

gaa tct ctg gtg gaa gcc acg gtg ggg gag cgt gtc aga atc cct gcg 1115  
Glu Ser Leu Val Glu Ala Thr Val Gly Glu Arg Val Arg Ile Pro Ala  
340 345 350

aag tac ctt ggt tac cca ccc cca gaa ata aaa tgg tat aaa aat gga 1163  
Lys Tyr Leu Gly Tyr Pro Pro Glu Ile Lys Trp Tyr Lys Asn Gly  
355 360 365

ata ccc ctt gag tcc aat cac aca att aaa gcg ggg cat gta ctg acg 1211  
Ile Pro Leu Glu Ser Asn His Thr Ile Lys Ala Gly His Val Leu Thr  
370 375 380

att atg gaa gtg agt gaa aga gac aca gga aat tac act gtc atc ctt 1259  
Ile Met Glu Val Ser Glu Arg Asp Thr Gly Asn Tyr Thr Val Ile Leu  
385 390 395 400

acc aat ccc att tca aag gag aag cag acg cat gtg gtc tct ctg gtt 1307  
Thr Asn Pro Ile Ser Lys Glu Lys Gln Ser His Val Val Ser Leu Val  
405 410 415

gtg tat gtc cca ccc cag att ggt gag aaa tct cta atc tct cct gtg 1355  
Val Tyr Val Pro Pro Gln Ile Gly Glu Lys Ser Leu Ile Ser Pro Val  
420 425 430

gat tcc tac cag tac ggc acc act caa acg ctg aca tgt acg gtc tat 1403  
Asp Ser Tyr Gln Tyr Gly Thr Thr Gln Thr Leu Thr Cys Thr Val Tyr  
435 440 445

gcc att cct ccc ccg cat cac atc cac tgg tat tgg cag ttg gag gaa 1451  
Ala Ile Pro Pro His His Ile His Trp Tyr Trp Gln Leu Glu Glu  
450 455 460

gag tgc gcc aac gag ccc agc cat gct gtc tca gtg aca aac cca tac 1499  
Glu Cys Ala Asn Glu Pro Ser His Ala Val Ser Val Thr Asn Pro Tyr  
465 470 475 480

cct tgt gaa gaa tgg aga agt gtg gag gac ttc cag gga gga aat aaa 1547  
Pro Cys Glu Glu Trp Arg Ser Val Glu Asp Phe Gln Gly Gly Asn Lys  
485 490 495

att gaa gtt aat aaa aat caa ttt gct cta att gaa gga aaa aac aaa 1595  
Ile Glu Val Asn Lys Asn Gln Phe Ala Leu Ile Glu Gly Lys Asn Lys

500

505

act gta agt acc ctt gtt atc caa gcg gca aat gtg tca gct ttg tac	1643
Thr Val Ser Thr Leu Val Ile Gln Ala Ala Asn Val Ser Ala Leu Tyr	
515 520 525	
aaa tgt gaa gcg gtc aac aaa gtc ggg aga gga gag agg gtg atc tcc	1691
Lys Cys Glu Ala Val Asn Lys Val Gly Arg Gly Glu Arg Val Ile Ser	
530 535 540	
ttc cac gtg acc agg ggt cct gaa att act ttg caa cct gac atg cag	1739
Phe His Val Thr Arg Gly Pro Glu Ile Thr Leu Gln Pro Asp Met Gln	
545 550 555 560	
ccc act gag cag gag agc gtg tct ttg tgg tgc act gca gac aga tct	1787
Pro Thr Glu Gln Glu Ser Val Ser Leu Trp Cys Thr Ala Asp Arg Ser	
565 570 575	
acg ttt gag aac ctc aca tgg tac aag ctt ggc cca cag cct ctg cca	1835
Thr Phe Glu Asn Leu Thr Trp Tyr Lys Leu Gly Pro Gln Pro Leu Pro	
580 585 590	
atc cat gtg gga gag ttg ccc aca cct gtt tgc aag aac ttg gat act	1883
Ile His Val Gly Glu Leu Pro Thr Pro Val Cys Lys Asn Leu Asp Thr	
595 600 605	
ctt tgg aaa ttg aat gcc acc atg ttc tct aat agc aca aat gac att	1931
Leu Trp Lys Leu Asn Ala Thr Met Phe Ser Asn Ser Thr Asn Asp Ile	
610 615 620	
ttg atc atg gag ctt aag aat gca tcc ttg cag gac caa gga gac tat	1979
Leu Ile Met Glu Leu Lys Asn Ala Ser Leu Gln Asp Gln Gly Asp Tyr	
625 630 635 640	
gtc tgc ctt gct caa gac agg aag acc aag aaa aga cat tgc gtg gtc	2027
Val Cys Leu Ala Gln Asp Arg Lys Thr Lys Lys Arg His Cys Val Val	
645 650 655	
agg cag ctc aca gtc cta gag cgt gtg gca ccc acg atc aca gga aac	2075
Arg Gln Leu Thr Val Leu Glu Arg Val Ala Pro Thr Ile Thr Gly Asn	
660 665 670	
ctg gaa aat cag acg aca agt att ggg gaa agc atc gaa gtc tca tgc	2123
Leu Glu Asn Gln Thr Thr Ser Ile Gly Glu Ser Ile Glu Val Ser Cys	
675 680 685	
acg gca tct ggg aat ccc cct cca cag atc atg tgg tat aaa gat aat	2171
Thr Ala Ser Gly Asn Pro Pro Gln Ile Met Trp Phe Lys Asp Asn	
690 695 700	
gag acc ctt gta gaa gac tca ggc att gta ttg aag gat ggg aac cgg	2219
Glu Thr Leu Val Glu Asp Ser Gly Ile Val Leu Lys Asp Gly Asn Arg	
705 710 715 720	
aac ctc act atc cgc aga gtg agg aag gag gac gaa ggc ctc tac acc	2267
Asn Leu Thr Ile Arg Arg Val Arg Lys Glu Asp Glu Gly Leu Tyr Thr	
725 730 735	
tgc cag gca tgc agt gtt ctt ggc tgt gca aaa gtg gag gca ttt ttc	2315
Cys Gln Ala Cys Ser Val Leu Gly Cys Ala Lys Val Glu Ala Phe Phe	
740 745 750	
ata ata gaa ggt gcc cag gaa aag acg aac ttg gaa	2351
Ile Ile Glu Gly Ala Gln Glu Lys Thr Asn Leu Glu	
755 760	

<210> 137  
<211> 764  
<212> PRT  
<213> Human

<400> 137

Met Gln Ser Lys Val Leu Leu Ala Val Ala Leu Trp Leu Cys Val Glu  
5 10 15

Thr Arg Ala Ala Ser Val Gly Leu Pro Ser Val Ser Leu Asp Leu Pro  
20 25 30

Arg Leu Ser Ile Gln Lys Asp Ile Leu Thr Ile Lys Ala Asn Thr Thr  
35 40 45

Leu Gln Ile Thr Cys Arg Gly Gln Arg Asp Leu Asp Trp Leu Trp Pro  
50 55 60

Asn Asn Gln Ser Gly Ser Glu Gln Arg Val Glu Val Thr Glu Cys Ser  
65 70 75 80

Asp Gly Leu Phe Cys Lys Thr Leu Thr Ile Pro Lys Val Ile Gly Asn  
85 90 95

Asp Thr Gly Ala Tyr Lys Cys Phe Tyr Arg Glu Thr Asp Leu Ala Ser  
100 105 110

Val Ile Tyr Val Tyr Val Gln Asp Tyr Arg Ser Pro Phe Ile Ala Ser  
115 120 125

Val Ser Asp Gln His Gly Val Val Tyr Ile Thr Glu Asn Lys Asn Lys  
130 135 140

Thr Val Val Ile Pro Cys Leu Gly Ser Ile Ser Asn Leu Asn Val Ser  
145 150 155 160

Leu Cys Ala Arg Tyr Pro Glu Lys Arg Phe Val Pro Asp Gly Asn Arg  
165 170 175

Ile Ser Trp Asp Ser Lys Lys Gly Phe Thr Ile Pro Ser Tyr Met Ile  
180 185 190

Ser Tyr Ala Gly Met Val Phe Cys Glu Ala Lys Ile Asn Asp Glu Ser  
195 200 205

Tyr Gln Ser Ile Met Tyr Ile Val Val Val Gly Tyr Arg Ile Tyr  
210 215 220

Asp Val Val Leu Ser Pro Ser His Gly Ile Glu Leu Ser Val Gly Glu  
225 230 235 240

Lys Leu Val Leu Asn Cys Thr Ala Arg Thr Glu Leu Asn Val Gly Ile  
245 250 255

Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys His Gln His Lys Lys Leu  
260 265 270

Val Asn Arg Asp Leu Lys Thr Gln Ser Gly Ser Glu Met Lys Lys Phe  
275 280 285

Leu Ser Thr Leu Thr Ile Asp Gly Val Thr Arg Ser Asp Gln Gly Leu  
290 295 300

Tyr Thr Cys Ala ~~Ala~~ Ser Gly Leu Met Thr Lys Lys ~~Ala~~ Ser Thr  
305 310 315 320

Phe Val Arg Val His Glu Lys Pro Phe Val Ala Phe Gly Ser Gly Met  
325 330 335

Glu Ser Leu Val Glu Ala Thr Val Gly Glu Arg Val Arg Ile Pro Ala  
340 345 350

Lys Tyr Leu Gly Tyr Pro Pro Glu Ile Lys Trp Tyr Lys Asn Gly  
355 360 365

Ile Pro Leu Glu Ser Asn His Thr Ile Lys Ala Gly His Val Leu Thr  
370 375 380

Ile Met Glu Val Ser Glu Arg Asp Thr Gly Asn Tyr Thr Val Ile Leu  
385 390 395 400

Thr Asn Pro Ile Ser Lys Glu Lys Gln Ser His Val Val Ser Leu Val  
405 410 415

Val Tyr Val Pro Pro Gln Ile Gly Glu Lys Ser Leu Ile Ser Pro Val  
420 425 430

Asp Ser Tyr Gln Tyr Gly Thr Thr Gln Thr Leu Thr Cys Thr Val Tyr  
435 440 445

Ala Ile Pro Pro Pro His His Ile His Trp Tyr Trp Gln Leu Glu Glu  
450 455 460

Glu Cys Ala Asn Glu Pro Ser His Ala Val Ser Val Thr Asn Pro Tyr  
465 470 475 480

Pro Cys Glu Glu Trp Arg Ser Val Glu Asp Phe Gln Gly Gly Asn Lys  
485 490 495

Ile Glu Val Asn Lys Asn Gln Phe Ala Leu Ile Glu Gly Lys Asn Lys  
500 505 510

Thr Val Ser Thr Leu Val Ile Gln Ala Ala Asn Val Ser Ala Leu Tyr  
515 520 525

Lys Cys Glu Ala Val Asn Lys Val Gly Arg Gly Glu Arg Val Ile Ser  
530 535 540

Phe His Val Thr Arg Gly Pro Glu Ile Thr Leu Gln Pro Asp Met Gln  
545 550 555 560

Pro Thr Glu Gln Glu Ser Val Ser Leu Trp Cys Thr Ala Asp Arg Ser  
565 570 575

Thr Phe Glu Asn Leu Thr Trp Tyr Lys Leu Gly Pro Gln Pro Leu Pro  
580 585 590

Ile His Val Gly Glu Leu Pro Thr Pro Val Cys Lys Asn Leu Asp Thr  
595 600 605

Leu Trp Lys Leu Asn Ala Thr Met Phe Ser Asn Ser Thr Asn Asp Ile  
610 615 620

Leu Ile Met Glu Leu Lys Asn Ala Ser Leu Gln Asp Gln Gly Asp Tyr  
625 630 635 640

Val Cys Leu Ala Gln Asp Arg Lys Thr Lys Lys Arg His Cys Val Val  
645 650 655

Arg Gln Leu Thr Val Leu Glu Arg Val Ala Pro Thr Ile Gly Asn  
660 665 670

Leu Glu Asn Gln Thr Thr Ser Ile Gly Glu Ser Ile Glu Val Ser Cys  
675 680 685

Thr Ala Ser Gly Asn Pro Pro Gln Ile Met Trp Phe Lys Asp Asn  
690 695 700

Glu Thr Leu Val Glu Asp Ser Gly Ile Val Leu Lys Asp Gly Asn Arg  
705 710 715 720

Asn Leu Thr Ile Arg Arg Val Arg Lys Glu Asp Glu Gly Leu Tyr Thr  
725 730 735

Cys Gln Ala Cys Ser Val Leu Gly Cys Ala Lys Val Glu Ala Phe Phe  
740 745 750

Ile Ile Glu Gly Ala Gln Glu Lys Thr Asn Leu Glu  
755 760

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/41372

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12P 12/08, 21/08; A61K 39/395  
US CL : 530/387.3; 435/326; 424/133.1

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
U.S. : 530/387.3; 435/326; 424/133.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Continuation Sheet

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ✓	Lu, D. Complete Inhibition of Vascular Endothelial Growth Factor (VEGF) Activities with a Bifunctional Diabody Directed against Both VEGF Kinase Receptors, fms-like Tyrosine Kinase Receptor and Kinase Insert Domain-containing Receptor. Cancer Research October 2001, Vol 61. pages 7002-7008, especially page 7005, Table 1, page 7004, and Figure 1.	1-5, and 23-42
Y ✓	Lu, D. Acquired Antagonistic Activity of a Bispecific Diabody Directed Against Two Different Epitopes on Vascular Endothelial Growth Factor Receptor 2. J. Immunol. Methods November 1999, Vol 230. No. 1-2, pages 159-71, especially abstract.	1-4, 24-28, 30-34, and 36-42

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"B" earlier application or patent published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

30 April 2003 (30.04.2003)

Date of mailing of the international search report

**30 JUN 2003**

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Phuong Huynh

*Christina Chan*

Telephone No. (703) 308-0196

**Continuation of B. FIELDS SEARCHED Item 3:**  
MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS on STN  
Chimeric VEGF receptor antibody, KDR, Flt-1, Flt-4, diabody, method making antibodies